{
  "mri-denial": {
    "slug": "mri-denial",
    "title": "Appealing MRI Denials",
    "default_procedure": "MRI Scan",
    "tagline": "Insurance often denies MRIs as 'not medically necessary'—here’s how to overturn it.",
    "hero_h1": "Appeal Your MRI Denial",
    "hero_subhead": "Don’t let \"not medically necessary\" stop you from getting real answers.",
    "intro": "MRIs get denied all the time — usually because the insurer wants cheaper imaging first or claims your symptoms don’t justify the scan. But if your doctor ordered it, there’s a strong chance you can overturn the denial with a clear appeal explaining why the MRI is clinically necessary.",
    "common_denial_reasons": [
      "Not medically necessary",
      "Try X-ray or PT first",
      "Insufficient documentation of symptoms",
      "Out-of-network imaging provider"
    ],
    "how_we_help": "We help you explain your symptoms, clinical history, and physician recommendations in a way insurers actually respond to. Upload your denial and we’ll generate a polished appeal letter you can submit today.",
    "cta": "Start your MRI appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Can I appeal an MRI denial if I already had the scan done?",
        "answer": "Yes. Even if the MRI already happened, you can still appeal the denial and ask the insurer to cover it. Your appeal will focus on why the scan was medically necessary at the time it was ordered."
      },
      {
        "question": "Do I need my doctor to write a letter for my MRI appeal?",
        "answer": "It helps a lot. Our letter generator can work with what you have, but a short note from your doctor explaining why the MRI was necessary can significantly strengthen your appeal."
      },
      {
        "question": "What if my insurer says I should have tried an X-ray first?",
        "answer": "Many guidelines support going straight to MRI when symptoms or red flags are serious enough. Your appeal should explain your symptoms, risks, and why an MRI was the appropriate first test."
      }
    ],
    "evidence_snippets": [
      "Clinical guidelines support MRI when there are neurologic deficits, red-flag symptoms, or failure of conservative treatment.",
      "Delays in appropriate imaging can lead to missed or worsened diagnoses, increased morbidity, and higher downstream costs.",
      "The requested MRI is consistent with evidence-based practice and standard of care for this clinical presentation."
    ],
    "pubmed_search_terms": [
      "MRI appropriateness criteria low back pain red flags",
      "evidence-based guidelines MRI neurologic symptoms",
      "impact of delayed MRI diagnosis outcomes"
    ]
  },
  "ct-scan-denial": {
    "slug": "ct-scan-denial",
    "title": "Appealing CT Scan Denials",
    "default_procedure": "CT Scan",
    "tagline": "Step-by-step help appealing CT scan denials, especially for urgent or diagnostic cases.",
    "hero_h1": "Appeal Your CT Scan Denial",
    "hero_subhead": "When your doctor orders it, insurers shouldn’t second-guess them.",
    "intro": "CT scans are often denied because insurers think the issue isn’t urgent or could be diagnosed another way. A strong appeal clarifies why your doctor chose a CT and why delay could harm your health.",
    "common_denial_reasons": [
      "Not medically necessary",
      "Alternate imaging recommended first",
      "No documentation of urgent symptoms"
    ],
    "how_we_help": "We help you articulate the clinical urgency and rationale behind your CT order, backed by your doctor’s notes and your symptoms.",
    "cta": "Start your CT scan appeal.",
    "faq": [
      {
        "question": "Why did my insurer deny my CT scan?",
        "answer": "Common reasons include claiming your condition isn't urgent, preferring another test first, or saying your symptoms weren’t clearly documented. Your appeal should address each of those points directly."
      },
      {
        "question": "Do I need ER or urgent care notes for my CT appeal?",
        "answer": "They help. If you have records from an ER or urgent visit, including them can show why your doctor felt a CT scan was needed quickly."
      },
      {
        "question": "Can I still appeal if I went ahead and got the CT scan anyway?",
        "answer": "Yes. You can appeal after the fact and ask for coverage, especially if your results showed something significant or matched the doctor’s concerns."
      }
    ],
    "evidence_snippets": [
      "CT imaging is recommended in many guidelines when serious pathology is suspected and rapid diagnosis affects management.",
      "Timely CT scans can reduce morbidity and mortality in conditions such as suspected stroke, pulmonary embolism, or abdominal emergencies.",
      "The requested CT is consistent with standard of care and clinical decision rules for this presentation."
    ],
    "pubmed_search_terms": [
      "CT scan emergency department diagnostic yield",
      "guidelines CT imaging acute abdominal pain",
      "clinical decision rules CT imaging"
    ]
  },
  "sleep-study-denial": {
    "slug": "sleep-study-denial",
    "title": "Appealing Sleep Study Denials",
    "default_procedure": "Sleep Study (Polysomnography or Home Study)",
    "tagline": "Insurers frequently require a home test first—learn how to appeal this and win.",
    "hero_h1": "Appeal Your Sleep Study Denial",
    "hero_subhead": "Whether in-lab or at home, testing for sleep disorders shouldn’t be a battle.",
    "intro": "Sleep studies are denied constantly — often because insurers want a home test first or don’t see enough documented symptoms. Your appeal can fix this.",
    "common_denial_reasons": [
      "Must complete home sleep test first",
      "Insufficient symptoms documented",
      "Repeat test not covered"
    ],
    "how_we_help": "We help you clarify symptoms like snoring, apnea episodes, daytime sleepiness, and medical risks, all of which support medical necessity.",
    "cta": "Start your sleep study appeal.",
    "faq": [
      {
        "question": "What symptoms should I mention in my sleep study appeal?",
        "answer": "Include loud snoring, witnessed apneas, gasping, morning headaches, daytime sleepiness, trouble focusing, and any work or driving safety concerns."
      },
      {
        "question": "Can I appeal if I need an in-lab study instead of a home test?",
        "answer": "Yes. You can explain why an in-lab study is safer or more accurate in your case, such as other medical conditions or prior inconclusive home tests."
      },
      {
        "question": "Do I have to wait for another denial to appeal?",
        "answer": "No. You usually have the right to file an internal appeal after the first denial. Check your plan’s deadline and file as soon as you can."
      }
    ],
    "evidence_snippets": [
      "Polysomnography is the standard diagnostic tool for obstructive sleep apnea and related disorders.",
      "Untreated sleep apnea is associated with cardiovascular disease, metabolic disorders, and increased accident risk.",
      "Early diagnosis and treatment of sleep disorders reduce long-term healthcare costs and improve quality of life."
    ],
    "pubmed_search_terms": [
      "polysomnography obstructive sleep apnea guidelines",
      "untreated sleep apnea cardiovascular risk",
      "home sleep apnea testing vs polysomnography"
    ]
  },
  "cpap-denial": {
    "slug": "cpap-denial",
    "title": "Appealing CPAP Denials",
    "default_procedure": "CPAP Machine or Supplies",
    "default_condition": "Sleep Apnea",
    "tagline": "Helpful for OSA patients denied CPAP devices or replacement supplies.",
    "hero_h1": "Appeal Your CPAP Denial",
    "hero_subhead": "Insurers often deny CPAP coverage despite your doctor's prescription.",
    "intro": "Insurers regularly deny CPAP machines and supplies, often claiming test results don't meet criteria or that compliance wasn’t proven.",
    "common_denial_reasons": [
      "Doesn’t meet AHI thresholds",
      "Non-compliant usage",
      "Home sleep study insufficient",
      "Replacement schedule not allowed"
    ],
    "how_we_help": "We help you appeal by asking questions and helping you explain symptoms, severity, diagnostic testing, or medical need for supplies or equipment replacement.",
    "cta": "Start your CPAP appeal.",
    "faq": [
      {
        "question": "What if my AHI is just below their cutoff?",
        "answer": "Your appeal can emphasize symptoms, comorbid conditions, and functional impairment. Many guidelines support treatment even at moderate AHI when symptoms are significant."
      },
      {
        "question": "How do I address a \"non-compliance\" denial?",
        "answer": "Explain barriers you faced, how you’ve addressed them, and include any updated compliance data from your device if available."
      },
      {
        "question": "Can I appeal denials for CPAP supplies and replacement parts?",
        "answer": "Yes. Supplies are part of keeping treatment effective. Your appeal can explain why replacements are needed to maintain therapy."
      }
    ],
    "evidence_snippets": [
      "Medical literature supports CPAP as a standard treatment option for obstructive sleep apnea when prescribed by a physician.",
      "Coverage continuity helps patients maintain the treatment plan their doctor has established.",
      "Many guidelines recognize CPAP as an appropriate treatment for patients who meet clinical criteria."
    ],
    "pubmed_search_terms": [
      "CPAP therapy outcomes obstructive sleep apnea",
      "cost effectiveness CPAP cardiovascular",
      "adherence CPAP treatment health outcomes"
    ]
  },
  "pt-ot-st-denial": {
    "slug": "pt-ot-st-denial",
    "title": "Appealing Physical/Occupational/Speech Therapy Denials",
    "default_procedure": "Physical / Occupational / Speech Therapy",
    "tagline": "Appeal visit-limit denials and claims insurers mark as 'maintenance only.'",
    "hero_h1": "Appeal Your Physical, Occupational, or Speech Therapy Denial",
    "hero_subhead": "Movement, recovery, and communication aren’t optional.",
    "intro": "Insurers often deny therapy by calling it \"maintenance care\" or limiting visit counts. Your appeal can correct that.",
    "common_denial_reasons": [
      "Maintenance only, not restorative",
      "Exceeded allowed visit limit",
      "Insufficient documentation of functional deficits"
    ],
    "how_we_help": "We help you explain your functional goals, progress, and clinician recommendations clearly — things insurers typically overlook.",
    "cta": "Start your therapy appeal.",
    "faq": [
      {
        "question": "What counts as \"medical necessity\" for therapy?",
        "answer": "Showing that therapy improves or prevents decline in mobility, strength, speech, or daily activities usually supports medical necessity."
      },
      {
        "question": "Can I appeal if I’ve hit the plan’s visit limit?",
        "answer": "Yes. Many plans allow exceptions when continued therapy is medically necessary. Your appeal can include progress notes and updated goals."
      },
      {
        "question": "Should my therapist provide documentation?",
        "answer": "Absolutely. Progress notes, functional assessments, and a short letter from your therapist can significantly strengthen your appeal."
      }
    ],
    "evidence_snippets": [
      "Rehabilitation therapies improve function, reduce disability, and can prevent more costly interventions or institutional care.",
      "Continuing therapy beyond arbitrary visit limits may be necessary when measurable gains are still being made.",
      "Therapy is considered medically necessary when it is expected to result in significant, sustained improvement in function."
    ],
    "pubmed_search_terms": [
      "physical therapy functional outcomes chronic conditions",
      "occupational therapy activities of daily living improvement",
      "speech therapy effectiveness communication disorders"
    ]
  },
  "mental-health-denial": {
    "slug": "mental-health-denial",
    "title": "Appealing Mental Health Care Denials",
    "default_procedure": "Psychiatry / Therapy Services",
    "tagline": "Mental health parity laws exist — let’s make insurers follow them.",
    "hero_h1": "Appeal Your Mental Health Care Denial",
    "hero_subhead": "Mental health care is real health care.",
    "intro": "Therapy and psychiatric care get denied for absurd reasons like \"not medically necessary\" or \"not enough impairment.\" Many of these denials violate mental health parity laws.",
    "common_denial_reasons": [
      "Not medically necessary",
      "Too frequent or insufficient symptoms",
      "Provider out-of-network"
    ],
    "how_we_help": "We can help you explain your symptoms, risks, impact on daily life, and your clinician’s treatment plan — which often turns denials around quickly.",
    "cta": "Start your mental health appeal.",
    "faq": [
      {
        "question": "What are mental health parity laws?",
        "answer": "Parity laws generally require insurers to cover mental health and substance use care on equal terms with medical and surgical care. Denials based on stricter rules may violate these laws."
      },
      {
        "question": "Can I appeal if my insurer reduced my therapy frequency?",
        "answer": "Yes. You can appeal a reduction or limit by showing that your current frequency is medically necessary and supported by your therapist or psychiatrist."
      },
      {
        "question": "Do I need to share very personal details in my appeal?",
        "answer": "You can focus on symptoms and how they affect work, school, relationships, and self-care. It should be honest but doesn’t require every personal detail."
      }
    ],
    "evidence_snippets": [
      "Evidence-based psychotherapy and psychiatric medication reduce symptoms, relapse risk, and overall healthcare utilization.",
      "Under-treatment of mental health conditions is associated with increased emergency visits, hospitalizations, and disability.",
      "Parity regulations support coverage of mental health treatment consistent with standards of care."
    ],
    "pubmed_search_terms": [
      "mental health treatment outcomes psychotherapy medication",
      "parity law impact insurance coverage mental health",
      "under-treatment depression healthcare utilization"
    ]
  },
  "infusion-therapy-denial": {
    "slug": "infusion-therapy-denial",
    "title": "Appealing Infusion Therapy Denials",
    "default_procedure": "Infusion Therapy",
    "tagline": "Covers IVIG, chemo, biologics, and more.",
    "hero_h1": "Appeal Your Infusion Therapy Denial",
    "hero_subhead": "When your doctor orders infusion therapy, insurers shouldn't stand in the way.",
    "intro": "Insurers deny infusions due to cost, preferred site-of-care, or claims of \"non-medical necessity.\" A strong appeal can reverse this.",
    "common_denial_reasons": [
      "Not medically necessary",
      "Wrong site-of-care (home vs hospital)",
      "Step therapy required first"
    ],
    "how_we_help": "We help you explain your diagnosis, risks of delaying treatment, and why the ordered site-of-care is necessary.",
    "cta": "Start your infusion appeal.",
    "faq": [
      {
        "question": "What is \"site-of-care\" and why does it matter?",
        "answer": "Insurers sometimes require infusions at certain locations, like outpatient centers instead of hospitals. Your appeal can explain why the chosen setting is safer or medically necessary."
      },
      {
        "question": "Can I appeal if they want me to switch to a different drug?",
        "answer": "Yes. Your appeal can explain why the prescribed medication is clinically appropriate and why alternatives may be less effective or riskier in your case."
      },
      {
        "question": "What if delaying infusion could make my condition worse?",
        "answer": "Make that explicit. Appeals are stronger when they clearly describe the risks of delay, including organ damage, flare-ups, or hospitalizations."
      }
    ],
    "evidence_snippets": [
      "Timely administration of infusion therapies reduces disease activity and prevents irreversible organ damage in many conditions.",
      "Site-of-care should be determined based on clinical safety and stability, not solely cost.",
      "Step therapy policies should not override evidence-based prescribing when prior treatments have failed or are contraindicated."
    ],
    "pubmed_search_terms": [
      "infusion therapy outcomes autoimmune",
      "site-of-care infusion safety home vs hospital",
      "step therapy impact biologic treatment delays"
    ],
    "alternatives": [
      "Some infused medications have subcutaneous versions that may have different coverage status.",
      "Ask your provider about biosimilars which may be on a preferred tier with your insurer.",
      "Home infusion vs. hospital/clinic infusion may have different coverage — discuss options with your provider."
    ],
    "assistance_programs": [
      {
        "name": "EntyvioConnect (Entyvio)",
        "url": "https://www.entyvio.com/copay-support",
        "description": "Eligible patients may pay as little as $5 per dose. Max $20,000/year benefit for commercial insurance."
      },
      {
        "name": "Janssen CarePath (Remicade, Simponi Aria)",
        "url": "https://www.jnjwithme.com/",
        "description": "Copay assistance and patient assistance programs for J&J infused medications."
      },
      {
        "name": "Genentech Access Solutions (Rituxan, Ocrevus)",
        "url": "https://www.genentech-access.com/",
        "description": "Copay assistance and patient assistance for Genentech infused therapies."
      },
      {
        "name": "Immune Deficiency Foundation Resources",
        "url": "https://primaryimmune.org/living-primary-immunodeficiency/get-support/find-other-support",
        "description": "Comprehensive list of manufacturer programs and independent foundations for infusion assistance."
      }
    ]
  },
  "ivig-denial": {
    "slug": "ivig-denial",
    "title": "Appealing IVIG Denials",
    "default_procedure": "IVIG Infusion",
    "tagline": "IVIG denials are common but often successfully appealed with proper documentation.",
    "hero_h1": "Appeal Your IVIG Denial",
    "hero_subhead": "IVIG denials are extremely common — but often reversible.",
    "intro": "IVIG denials often happen because insurers don't understand the exact diagnostic criteria or disease progression.",
    "common_denial_reasons": [
      "Insufficient documentation of autoimmune diagnosis",
      "Other treatments must be tried first",
      "Home infusion only"
    ],
    "how_we_help": "We help you explain diagnostic markers, prior treatments, symptom history, and clinical risks of delaying IVIG.",
    "cta": "Start your IVIG appeal.",
    "faq": [
      {
        "question": "Why is IVIG so commonly denied?",
        "answer": "IVIG is expensive, so insurers scrutinize it heavily. Denials often focus on technical criteria, missing labs, or step therapy requirements."
      },
      {
        "question": "What documentation should I include for IVIG appeals?",
        "answer": "Include lab results, biopsy findings, prior treatment history, neurologic or rheumatologic exams, and your specialist's notes."
      },
      {
        "question": "Can I appeal if they want me to try cheaper treatments again?",
        "answer": "Yes. Your appeal can show what you've already tried, why it failed, and why repeating it is unlikely to help and may be harmful."
      }
    ],
    "evidence_snippets": [
      "Professional medical guidelines include IVIG as a treatment option for various conditions when prescribed by a specialist.",
      "Your specialist's documentation of diagnosis and treatment rationale is essential for a successful appeal.",
      "Coverage determinations should follow disease-specific criteria rather than blanket cost-based denials."
    ],
    "pubmed_search_terms": [
      "IVIG autoimmune neuropathy guidelines",
      "IVIG treatment outcomes immune thrombocytopenia",
      "evidence-based indications for intravenous immunoglobulin"
    ],
    "alternatives": [
      "Subcutaneous immunoglobulin (SCIG) may be an alternative with different coverage criteria for some conditions.",
      "For some conditions, plasma exchange may be covered differently while you appeal.",
      "Ask your provider about different IVIG brands, as formulary coverage varies by manufacturer."
    ],
    "assistance_programs": [
      {
        "name": "Grifols Patient Assistance (Gamunex-C)",
        "url": "https://www.gamunex-c.com/patient-resources",
        "description": "Help with deductibles, copays, and coinsurance. Call 1-888-MYGAMUNEX (1-888-694-2686)."
      },
      {
        "name": "CSL Behring Patient Support (Privigen, Hizentra)",
        "url": "https://www.cslbehring.com/patients",
        "description": "Patient assistance for uninsured/underinsured. Copay support for commercially insured."
      },
      {
        "name": "Octapharma Copay Program (Octagam, Panzyga)",
        "url": "https://www.octapharmausa.com/patients",
        "description": "Eligible patients may pay as little as $0 per treatment with commercial insurance."
      },
      {
        "name": "Immune Deficiency Foundation Resources",
        "url": "https://primaryimmune.org/living-primary-immunodeficiency/get-support/find-other-support",
        "description": "Comprehensive list of manufacturer programs and independent foundations for IVIG assistance."
      },
      {
        "name": "GBS/CIDP Foundation Financial Resources",
        "url": "https://www.gbs-cidp.org/support/resources/financial-assistance-resources/",
        "description": "Financial assistance resources specifically for GBS and CIDP patients needing IVIG."
      }
    ]
  },
  "biologic-denial": {
    "slug": "biologic-denial",
    "title": "Appealing Biologic Medication Denials",
    "default_procedure": "Biologic Medication",
    "tagline": "Help appealing biologic denials for conditions like RA, Crohn's, and psoriasis.",
    "hero_h1": "Appeal Your Biologic Medication Denial",
    "hero_subhead": "Humira, Skyrizi, Stelara, Entyvio, and others are routinely denied.",
    "intro": "Biologics for RA, Crohn's, psoriasis and more are often denied for step therapy or \"insufficient severity.\"",
    "common_denial_reasons": [
      "Must try cheaper medications first",
      "Condition not severe enough",
      "Off-label use not covered"
    ],
    "how_we_help": "We help you articulate clinical severity, treatment failures, diagnostic evidence, and medical rationale that insurers need to see.",
    "cta": "Start your biologic appeal.",
    "faq": [
      {
        "question": "What is \"step therapy\" and how do I fight it?",
        "answer": "Step therapy means the insurer wants you to fail cheaper drugs first. Your appeal can show that you've already tried and failed them, or that they're unsafe or inappropriate for you."
      },
      {
        "question": "What if my biologic is off-label for my condition?",
        "answer": "Some off-label uses are still supported by strong evidence. Your appeal can cite studies and guidelines that support the prescription."
      },
      {
        "question": "Should my specialist be involved in my appeal?",
        "answer": "Yes, ideally. A short letter from your specialist explaining why this biologic is necessary can make a big difference."
      }
    ],
    "evidence_snippets": [
      "Professional guidelines include biologics as treatment options for various autoimmune conditions when prescribed by a specialist.",
      "Your rheumatologist, gastroenterologist, or dermatologist's treatment plan is key evidence for your appeal.",
      "Documentation of prior treatment attempts and their outcomes strengthens appeals for biologic coverage."
    ],
    "pubmed_search_terms": [
      "biologic therapy rheumatoid arthritis treat-to-target",
      "biologic agents inflammatory bowel disease guidelines",
      "delayed biologic treatment outcomes autoimmune"
    ],
    "alternatives": [
      "While fighting your denial, ask your provider about biosimilar options which may have different coverage status.",
      "Some conditions may respond to conventional DMARDs (like methotrexate) as a bridge while appealing.",
      "Different biologics with similar mechanisms may have better formulary status with your insurer."
    ],
    "assistance_programs": [
      {
        "name": "myAbbVie Assist (Humira, Skyrizi, Rinvoq)",
        "url": "https://www.abbvie.com/patients/patient-support/patient-assistance.html",
        "description": "Free medication for qualifying uninsured/underinsured patients. Income limits apply."
      },
      {
        "name": "HUMIRA Complete Savings Card",
        "url": "https://www.humira.com/humira-complete/cost-and-copay",
        "description": "Commercially insured patients may pay as little as $0/month. Not for government insurance."
      },
      {
        "name": "Skyrizi Complete Savings Card",
        "url": "https://www.skyrizi.com/skyrizi-complete/save-on-skyrizi-costs",
        "description": "Eligible commercially insured patients may pay as little as $0 per dose. Max $14,000/year benefit."
      },
      {
        "name": "Janssen CarePath (Stelara)",
        "url": "https://www.jnjwithme.com/patient/stelara/cost-support/",
        "description": "Eligible patients pay $5 per dose with commercial insurance. Patient assistance also available."
      },
      {
        "name": "EntyvioConnect (Entyvio)",
        "url": "https://www.entyvio.com/copay-support",
        "description": "Eligible patients may pay as little as $5 per dose. Max $20,000/year benefit for commercial insurance."
      },
      {
        "name": "COSENTYX Connect",
        "url": "https://www.cosentyx.com/all/treatment-cost",
        "description": "84% of eligible patients paid $0 out of pocket. Up to 2 years free while appealing denials."
      },
      {
        "name": "Enbrel Co-Pay Program",
        "url": "https://www.enbrel.com/support",
        "description": "Eligible commercially insured patients may pay as little as $0 per dose."
      }
    ]
  },
  "oxygen-therapy-denial": {
    "slug": "oxygen-therapy-denial",
    "title": "Appealing Oxygen Therapy Denials",
    "default_procedure": "Home Oxygen Therapy",
    "tagline": "Help appealing oxygen therapy denials when your doctor has prescribed it.",
    "hero_h1": "Appeal Your Oxygen Therapy Denial",
    "hero_subhead": "COPD and pulmonary patients are denied oxygen far too often.",
    "intro": "Oxygen therapy is frequently denied over narrow testing thresholds or documentation gaps.",
    "common_denial_reasons": [
      "O2 saturation not low enough",
      "Home oxygen setup not justified",
      "Equipment replacement too soon"
    ],
    "how_we_help": "We help you explain symptoms, functional limits, risks, and test results to support medical necessity.",
    "cta": "Start your oxygen therapy appeal.",
    "faq": [
      {
        "question": "Do I need a specific oxygen saturation number for coverage?",
        "answer": "Many plans use specific thresholds, but your appeal can explain your real-world symptoms, desaturations with activity, and other risk factors."
      },
      {
        "question": "Can I appeal replacement denials for oxygen equipment?",
        "answer": "Yes. Your appeal can document wear, malfunction, and safety issues with old equipment."
      },
      {
        "question": "Should I include my pulmonary function tests?",
        "answer": "If you have them, yes. PFTs, six-minute walk tests, and oximetry reports can all support your appeal."
      }
    ],
    "evidence_snippets": [
      "Your pulmonologist's prescription and clinical documentation are the foundation of a strong appeal.",
      "Medical guidelines support oxygen therapy for patients who meet specific clinical criteria determined by their physician.",
      "Coverage decisions should consider your physician's assessment of functional impairment and documented test results."
    ],
    "pubmed_search_terms": [
      "long term oxygen therapy survival COPD",
      "oxygen therapy chronic hypoxemia guidelines",
      "home oxygen functional outcomes pulmonary disease"
    ]
  },
  "wheelchair-denial": {
    "slug": "wheelchair-denial",
    "title": "Appealing Wheelchair or Mobility Aid Denials",
    "default_procedure": "Wheelchair / Mobility Device",
    "tagline": "Mobility is a medical necessity — not a luxury.",
    "hero_h1": "Appeal Your Wheelchair or Mobility Aid Denial",
    "hero_subhead": "Wheelchairs and mobility aids get denied constantly for bad reasons.",
    "intro": "Insurers often deny mobility devices due to coding issues, documentation gaps, or \"not medically necessary\" claims.",
    "common_denial_reasons": [
      "Not medically necessary",
      "Cheaper device required",
      "Insufficient documentation of mobility limitation"
    ],
    "how_we_help": "We help you present clear functional limitations, clinician recommendations, and why the specific device is medically required.",
    "cta": "Start your mobility appeal.",
    "faq": [
      {
        "question": "What should I say about my daily activities?",
        "answer": "Explain how walking or standing affects you, including pain, falls, fatigue, and whether you can safely get around at home or in the community without a device."
      },
      {
        "question": "Can I appeal for a power chair instead of a manual one?",
        "answer": "Yes. Your appeal should explain why you cannot effectively use a manual chair, such as limited arm strength or endurance."
      },
      {
        "question": "Should my PT or OT help with the appeal?",
        "answer": "If you have a mobility evaluation from PT or OT, including it with your appeal can be very persuasive."
      }
    ],
    "evidence_snippets": [
      "Appropriate mobility devices reduce fall risk, maintain independence, and can prevent institutionalization.",
      "Choosing the correct type of wheelchair based on functional needs is cost-effective over time.",
      "Coverage determinations should consider safety, independence, and long-term outcomes."
    ],
    "pubmed_search_terms": [
      "wheelchair prescription functional outcomes",
      "mobility aids fall risk reduction elderly",
      "power wheelchair cost effectiveness independence"
    ]
  },
  "surgery-denial": {
    "slug": "surgery-denial",
    "title": "Appealing Surgery Denials",
    "default_procedure": "Surgery",
    "tagline": "When your doctor says it’s necessary, insurers shouldn’t overrule them.",
    "hero_h1": "Appeal Your Surgery Denial",
    "hero_subhead": "Surgery denials often rely on outdated or incorrect standards.",
    "intro": "Surgeries get denied because insurers think conservative care hasn’t been exhausted or symptoms aren’t severe enough.",
    "common_denial_reasons": [
      "Conservative treatments not completed",
      "Insufficient imaging or clinical documentation",
      "Procedure considered elective"
    ],
    "how_we_help": "We help you document severity, prior treatments, imaging findings, and medical necessity.",
    "cta": "Start your surgery appeal.",
    "faq": [
      {
        "question": "What does \"conservative care\" mean in surgery denials?",
        "answer": "Insurers usually mean treatments like medication, physical therapy, or injections. Your appeal should show what you’ve tried and why surgery is now appropriate."
      },
      {
        "question": "Can I appeal if they called my surgery \"elective\"?",
        "answer": "Yes. Your appeal can explain the medical consequences of delaying surgery, including pain, disability, or progression of disease."
      },
      {
        "question": "Do I need my surgeon to help with the appeal?",
        "answer": "A short letter from your surgeon outlining the medical necessity, risks of delay, and expected benefits of surgery can be very helpful."
      }
    ],
    "evidence_snippets": [
      "For many conditions, timely surgery improves pain, function, and long-term outcomes compared to prolonged conservative care.",
      "Delaying indicated surgery may lead to irreversible damage or more complex procedures later.",
      "Coverage determinations should account for specialist recommendations and evidence-based surgical indications."
    ],
    "pubmed_search_terms": [
      "timing of surgery outcomes orthopedic",
      "conservative management vs surgery comparative effectiveness",
      "elective vs medically necessary surgery insurance"
    ]
  },
  "implantable-device-denial": {
    "slug": "implantable-device-denial",
    "title": "Appealing Implantable Device Denials",
    "default_procedure": "Implantable Device or Medical Implant",
    "tagline": "Implants can be life-changing — insurers shouldn’t deny them lightly.",
    "hero_h1": "Appeal Your Implantable Device Denial",
    "hero_subhead": "Spinal stimulators, cardiac devices, and pain pumps are often denied for cost reasons.",
    "intro": "Insurers often deny implants due to cost, labeling them \"experimental\" or requiring unnecessary steps.",
    "common_denial_reasons": [
      "Experimental or investigational",
      "Not medically necessary",
      "Alternative treatment recommended"
    ],
    "how_we_help": "We help you outline clinical justification, symptom history, and why non-implant treatments were insufficient.",
    "cta": "Start your implant appeal.",
    "faq": [
      {
        "question": "Why did they call my implant \"experimental\"?",
        "answer": "Insurers sometimes use older policy language that doesn’t reflect current evidence. Your appeal can cite up-to-date studies and guidelines."
      },
      {
        "question": "What if I’ve already tried other treatments?",
        "answer": "Your appeal should list each prior treatment, how long you tried it, and why it failed or caused side effects."
      },
      {
        "question": "Should my specialist provide device-specific information?",
        "answer": "Yes. Manufacturer and clinical data, plus your specialist’s letter, can directly counter \"experimental\" or \"not necessary\" claims."
      }
    ],
    "evidence_snippets": [
      "Implantable devices such as spinal cord stimulators have demonstrated efficacy in reducing pain and improving function in selected patients.",
      "Cardiac devices like ICDs and pacemakers reduce mortality in appropriately selected populations.",
      "Implant coverage decisions should align with FDA indications and specialty society guidelines."
    ],
    "pubmed_search_terms": [
      "spinal cord stimulation chronic pain outcomes",
      "implantable cardioverter defibrillator mortality benefit",
      "guidelines implantable medical devices indications"
    ]
  },
  "pain-management-denial": {
    "slug": "pain-management-denial",
    "title": "Appealing Pain Management Denials",
    "default_procedure": "Pain Management Treatment",
    "tagline": "Help appealing denials for pain procedures your doctor has recommended.",
    "hero_h1": "Appeal Your Pain Management Treatment Denial",
    "hero_subhead": "Pain care gets denied constantly — we can help reverse that.",
    "intro": "Pain treatments get denied because insurers love to call them \"experimental\" or require weeks of PT first.",
    "common_denial_reasons": [
      "Experimental / investigational",
      "Conservative care required first",
      "Not enough clinical documentation"
    ],
    "how_we_help": "We help you articulate diagnosis, severity, prior treatments, and clinical justification for your pain plan.",
    "cta": "Start your pain management appeal.",
    "faq": [
      {
        "question": "Why do they say my injections are \"experimental\"?",
        "answer": "Many interventional pain procedures have guideline support. Your appeal can reference those guidelines and your past treatment failures."
      },
      {
        "question": "Do I have to keep doing PT before getting pain procedures?",
        "answer": "Not always. If you’ve already tried PT or cannot tolerate it, your appeal should explain that and why procedures are now appropriate."
      },
      {
        "question": "Should I describe how pain affects my daily life?",
        "answer": "Yes. Include how pain limits walking, work, sleep, caregiving, and other activities. That helps show why treatment is medically necessary."
      }
    ],
    "evidence_snippets": [
      "Interventional pain procedures can reduce pain scores, improve function, and decrease reliance on systemic medications.",
      "For some patients, procedures provide safer, targeted relief than chronic opioid therapy.",
      "Coverage decisions should follow pain society guidelines and individualized treatment planning."
    ],
    "pubmed_search_terms": [
      "epidural steroid injection chronic back pain outcomes",
      "radiofrequency ablation facet joint pain effectiveness",
      "interventional pain management guidelines"
    ]
  },
  "prenatal-denial": {
    "slug": "prenatal-denial",
    "title": "Appealing Prenatal Care Denials",
    "default_procedure": "Prenatal Care / Ultrasound",
    "tagline": "Pregnancy care should never be a fight.",
    "hero_h1": "Appeal Your Prenatal Care Denial",
    "hero_subhead": "Ultrasounds and prenatal monitoring are essential care.",
    "intro": "Prenatal care often gets denied due to coding errors or nonsense \"not medically necessary\" claims.",
    "common_denial_reasons": [
      "Too many ultrasounds",
      "Screening not medically necessary",
      "Provider out of network"
    ],
    "how_we_help": "We help you clarify risks, symptoms, and physician recommendations.",
    "cta": "Start your prenatal care appeal.",
    "faq": [
      {
        "question": "Why did they say I had too many ultrasounds?",
        "answer": "Some plans only expect a small number of scans. Your appeal can explain high-risk factors or complications that justified additional imaging."
      },
      {
        "question": "Can I appeal if they denied prenatal labs?",
        "answer": "Yes. Many labs are standard of care in pregnancy. Your appeal can reference guidelines and any risk factors you have."
      },
      {
        "question": "What if my OB is out-of-network?",
        "answer": "You can appeal in some cases, especially if there is limited access to in-network providers or continuity of care concerns."
      }
    ],
    "evidence_snippets": [
      "Adequate prenatal care and appropriate fetal monitoring are associated with better maternal and neonatal outcomes.",
      "High-risk pregnancies often require more frequent imaging or testing than uncomplicated pregnancies.",
      "Coverage should reflect obstetric guidelines and individualized risk factors, not a fixed number of visits or scans."
    ],
    "pubmed_search_terms": [
      "prenatal care outcomes maternal neonatal",
      "high risk pregnancy ultrasound frequency guidelines",
      "antenatal testing evidence-based recommendations"
    ]
  },
  "breast-imaging-denial": {
    "slug": "breast-imaging-denial",
    "title": "Appealing Breast Imaging Denials",
    "default_procedure": "Mammogram / Breast MRI / Ultrasound",
    "tagline": "Early detection saves lives — denials shouldn’t stand in the way.",
    "hero_h1": "Appeal Your Breast Imaging Denial",
    "hero_subhead": "High-risk screening often gets denied — your appeal can fix that.",
    "intro": "Mammograms, ultrasounds, and breast MRIs can be denied when insurers claim you're not \"high-risk enough.\"",
    "common_denial_reasons": [
      "High-risk criteria not met",
      "Routine screening too early",
      "Diagnostic imaging not justified"
    ],
    "how_we_help": "We help you explain risk factors, symptoms, and why additional imaging was recommended.",
    "cta": "Start your breast imaging appeal.",
    "faq": [
      {
        "question": "What counts as \"high risk\" for extra breast imaging?",
        "answer": "Family history, genetic mutations, prior chest radiation, and certain biopsy results can all count. Your appeal should list your risk factors clearly."
      },
      {
        "question": "Can I appeal if they denied a diagnostic mammogram or MRI?",
        "answer": "Yes. Your appeal can explain your symptoms, prior imaging findings, and why your clinician ordered diagnostic testing instead of routine screening."
      },
      {
        "question": "Does age matter for my appeal?",
        "answer": "Many guidelines allow earlier or more frequent imaging for high-risk people. Your appeal can cite these exceptions."
      }
    ],
    "evidence_snippets": [
      "Appropriate breast imaging reduces late-stage cancer diagnoses and improves survival.",
      "High-risk populations benefit from supplemental imaging such as MRI in addition to mammography.",
      "Coverage decisions should consider individual risk rather than a one-size-fits-all age cutoff."
    ],
    "pubmed_search_terms": [
      "breast cancer screening high risk MRI",
      "supplemental breast MRI outcomes",
      "breast imaging guidelines high risk women"
    ]
  },
  "ffs-denial": {
    "slug": "ffs-denial",
    "title": "Appealing Facial Feminization Surgery (FFS) Denials",
    "default_procedure": "Facial Feminization Surgery (FFS)",
    "default_condition": "Gender Dysphoria",
    "tagline": "Insurers often incorrectly classify FFS as cosmetic — appeals can change that.",
    "hero_h1": "Appeal Your FFS Denial",
    "hero_subhead": "Insurers often deny FFS incorrectly as \"cosmetic\" — your appeal can address this.",
    "intro": "FFS is frequently denied by insurers who misclassify it as cosmetic. Appeals succeed when they clearly document your diagnosis, your provider's clinical recommendations, and alignment with WPATH standards.",
    "common_denial_reasons": [
      "Incorrectly deemed cosmetic",
      "Insufficient documentation of gender dysphoria",
      "Missing mental health evaluation notes",
      "Provider out-of-network or no contract for FFS"
    ],
    "how_we_help": "We help you document dysphoria, functional impairments, safety concerns, and WPATH-consistent medical necessity. We also help present your provider’s clinical support in a way insurers respond to.",
    "cta": "Start your FFS appeal.",
    "faq": [
      {
        "question": "Why did my insurer call FFS \"cosmetic\"?",
        "answer": "Many plans use outdated language that ignores current medical and professional guidance. Your appeal can explain how FFS treats gender dysphoria and improves safety, not appearance for its own sake."
      },
      {
        "question": "Do I need letters from therapists or mental health providers?",
        "answer": "Often yes. Including letters that diagnose gender dysphoria and support FFS as medically necessary can significantly strengthen your appeal."
      },
      {
        "question": "Can I appeal if only some FFS procedures were denied?",
        "answer": "Yes. You can appeal specific components and explain how each one affects your dysphoria, safety, or ability to be perceived as your correct gender."
      }
    ],
    "evidence_snippets": [
      "Your provider's documentation of diagnosis and treatment recommendations is essential for your appeal.",
      "WPATH Standards of Care address facial gender-affirming procedures as part of comprehensive care.",
      "Professional guidelines can be cited in appeals to counter insurer claims that FFS is purely cosmetic."
    ],
    "pubmed_search_terms": [
      "facial feminization surgery quality of life gender dysphoria",
      "gender affirming facial surgery mental health outcomes",
      "WPATH facial gender affirming surgery medical necessity"
    ]
  },
  "top-surgery-masc-denial": {
    "slug": "top-surgery-masc-denial",
    "title": "Appealing Transmasculine Top Surgery Denials",
    "default_procedure": "Chest Reconstruction (Top Surgery)",
    "default_condition": "Gender Dysphoria",
    "tagline": "If your provider recommended top surgery, we can help you appeal the denial.",
    "hero_h1": "Appeal Your Top Surgery Denial",
    "hero_subhead": "Insurers often demand outdated or unnecessary requirements — we help you push back.",
    "intro": "Top surgery denials typically rely on outdated guidelines or incorrect criteria. A strong appeal focuses on your provider's recommendations and alignment with current standards of care.",
    "common_denial_reasons": [
      "Not medically necessary",
      "BMI requirements or arbitrary weight rules",
      "Requests for excessive therapy letters",
      "Incorrectly labeled cosmetic"
    ],
    "how_we_help": "We help you cite WPATH standards, document dysphoria and functional limitations, and present your provider’s letter in a format insurers can’t easily ignore.",
    "cta": "Start your top surgery appeal.",
    "faq": [
      {
        "question": "Do I have to meet a specific BMI to get coverage?",
        "answer": "Many insurers use arbitrary BMI cutoffs that don’t reflect individualized risk. Your appeal can address safety planning without using BMI as an absolute barrier."
      },
      {
        "question": "Can I appeal if they want more therapy letters than WPATH suggests?",
        "answer": "Yes. You can point to WPATH standards and explain that excessive gatekeeping is not clinically justified."
      },
      {
        "question": "Should I talk about binding in my appeal?",
        "answer": "Yes, if it’s relevant. You can describe pain, skin damage, breathing issues, and functional problems from binding, which support medical necessity for surgery."
      }
    ],
    "evidence_snippets": [
      "Your provider's documentation and letters supporting the surgery are the foundation of a strong appeal.",
      "WPATH Standards of Care can be cited in appeals to counter arbitrary insurer requirements.",
      "Professional guidelines address criteria for chest reconstruction that your appeal can reference."
    ],
    "pubmed_search_terms": [
      "gender affirming chest surgery mental health outcomes",
      "top surgery transmasculine quality of life",
      "chest binding physical health effects"
    ]
  },
  "top-surgery-fem-denial": {
    "slug": "top-surgery-fem-denial",
    "title": "Appealing Transfeminine Breast Augmentation Denials",
    "default_procedure": "Breast Augmentation (Gender-Affirming)",
    "default_condition": "Gender Dysphoria",
    "tagline": "Breast augmentation for transfeminine people is gender-affirming care, not cosmetic.",
    "hero_h1": "Appeal Your Breast Augmentation Denial",
    "hero_subhead": "Many insurers rely on outdated criteria — appeals often succeed with proper documentation.",
    "intro": "Gender-affirming breast augmentation is frequently denied as \"cosmetic,\" even when medically necessary. A proper appeal reframes the request according to WPATH and clinical needs.",
    "common_denial_reasons": [
      "Incorrectly deemed cosmetic",
      "Claim that hormones should be continued longer first",
      "Insufficient dysphoria documentation",
      "Provider out-of-network"
    ],
    "how_we_help": "We help you build a strong appeal documenting medical necessity, dysphoria reduction aligned with WPATH SOC8.",
    "cta": "Start your appeal.",
    "faq": [
      {
        "question": "How long do I have to be on hormones before appealing?",
        "answer": "Insurers sometimes require a minimum hormone duration, but this should be individualized. Your appeal can explain your actual development and ongoing dysphoria. Many plans reference the WPATH standards of care which have changed so checking the version in your plan documents can help."
      },
      {
        "question": "Should I include photos in my appeal?",
        "answer": "Most appeals focus on dysphoria, physical development, and mental health impact rather than photos."
      },
      {
        "question": "Can I appeal if I’m nonbinary or not fully out?",
        "answer": "Yes. The key is documenting your gender dysphoria, your goals, and your provider’s support, not a specific label or coming-out timeline."
      }
    ],
    "evidence_snippets": [
      "Gender-affirming breast procedures are associated with improved body image and mental health in transfeminine patients.",
      "Breast augmentation can reduce misgendering and social anxiety, improving daily functioning.",
      "Guidelines increasingly support chest procedures as medically necessary components of gender-affirming care."
    ],
    "pubmed_search_terms": [
      "gender affirming breast augmentation outcomes transfeminine",
      "chest surgery body image transgender women",
      "WPATH chest surgery medical necessity transfeminine"
    ]
  },
  "electrolysis-denial": {
    "slug": "electrolysis-denial",
    "title": "Appealing Electrolysis & Gender-Affirming Hair Removal Denials",
    "default_procedure": "Electrolysis / Laser Hair Removal (Gender-Affirming)",
    "default_condition": "Gender Dysphoria",
    "tagline": "Hair removal is often required for surgeries — insurers still deny it as cosmetic.",
    "hero_h1": "Appeal Your Electrolysis Denial",
    "hero_subhead": "Gender-affirming hair removal is medically necessary for many people, especially pre-op.",
    "intro": "Electrolysis and laser hair removal are often necessary before genital surgeries and to reduce dysphoria. Insurers still deny them as cosmetic despite clear surgical guidelines.",
    "common_denial_reasons": [
      "Incorrectly classified as cosmetic",
      "Not deemed medically necessary for surgery prep",
      "Insufficient documentation or referral",
      "Claim that it is purely aesthetic"
    ],
    "how_we_help": "We help you show medical necessity and when applicable clarify surgical requirements that can help turn these denials around.",
    "cta": "Start your electrolysis appeal.",
    "faq": [
      {
        "question": "Why do surgeons require hair removal before some surgeries?",
        "answer": "Pre-op hair removal can prevent complications like hair growth where it shouldn’t be and reduce infection risk. Your appeal can cite your surgeon’s requirements."
      },
      {
        "question": "Can I appeal if I’m not having surgery but still need hair removal?",
        "answer": "Yes. Hair removal can still be medically necessary to treat severe dysphoria or safety concerns even when surgery isn’t planned."
      },
      {
        "question": "Do I need a referral from a surgeon or endocrinologist?",
        "answer": "It helps. A letter stating hair removal is medically necessary for your gender-affirming care can strengthen your appeal."
      }
    ],
    "evidence_snippets": [
      "Hair removal is a standard preoperative requirement in many genital reconstruction protocols.",
      "Gender-affirming hair removal can reduce dysphoria and improve mental health and social functioning.",
      "Classifying medically necessary hair removal as purely cosmetic is inconsistent with contemporary guidelines for gender-affirming care."
    ],
    "pubmed_search_terms": [
      "hair removal preoperative vaginoplasty protocol",
      "gender affirming hair removal mental health outcomes",
      "WPATH hair removal medical necessity transgender"
    ]
  },
  "voice-therapy-denial": {
    "slug": "voice-therapy-denial",
    "title": "Appealing Voice Therapy Denials",
    "default_procedure": "Voice Therapy (Gender-Affirming)",
    "default_condition": "Gender Dysphoria",
    "tagline": "Voice therapy is medically necessary gender-affirming care — not elective.",
    "hero_h1": "Appeal Your Voice Therapy Denial",
    "hero_subhead": "Insurers often misclassify voice work as cosmetic or elective — which is incorrect.",
    "intro": "Gender-affirming voice therapy reduces dysphoria, improves safety, and supports communication. Denials often rely on outdated coverage policies.",
    "common_denial_reasons": [
      "Considered cosmetic",
      "No speech pathology notes provided",
      "Insufficient documentation of dysphoria or vocal strain",
      "Provider out-of-network"
    ],
    "how_we_help": "We help you explain clinical necessity, communication limitations, and dysphoria impacts — key elements insurers often overlook.",
    "cta": "Start your voice therapy appeal.",
    "faq": [
      {
        "question": "Why does my insurer think voice therapy is cosmetic?",
        "answer": "Old policies treat voice only as appearance-related. Your appeal can explain how misgendering, safety concerns, and vocal strain make therapy medically necessary."
      },
      {
        "question": "Do I need an evaluation from a speech-language pathologist?",
        "answer": "It’s very helpful. An SLP’s assessment of your current voice, goals, and any strain or pain can support medical necessity."
      },
      {
        "question": "Can I appeal if I’ve already started voice therapy and they won’t cover more sessions?",
        "answer": "Yes. Your appeal can show progress made so far and why continued sessions are needed to reach safe, sustainable vocal patterns. However, retroactive coverage for sessions already paid for may be more difficult to achieve if \"prior authorization\" is required."
      }
    ],
    "evidence_snippets": [
      "Gender-affirming voice therapy improves vocal satisfaction, reduces dysphoria, and can decrease vocal strain.",
      "Voice training can reduce misgendering and associated anxiety, improving daily functioning and mental health.",
      "Professional groups recognize gender-affirming voice therapy as a legitimate scope of speech-language pathology practice."
    ],
    "pubmed_search_terms": [
      "gender affirming voice therapy transgender outcomes",
      "voice therapy transgender women satisfaction dysphoria",
      "speech language pathology gender affirming voice care"
    ]
  },
  "voice-surgery-denial": {
    "slug": "voice-surgery-denial",
    "title": "Appealing Voice Surgery Denials",
    "default_procedure": "Vocal Feminization / Masculinization Surgery",
    "default_condition": "Gender Dysphoria",
    "tagline": "Voice surgery is medically necessary for many trans people, not cosmetic.",
    "hero_h1": "Appeal Your Voice Surgery Denial",
    "hero_subhead": "Insurers frequently deny voice surgeries due to outdated criteria.",
    "intro": "Voice surgeries are life-changing and medically necessary for many trans people. Insurers often deny them as cosmetic despite evidence to the contrary.",
    "common_denial_reasons": [
      "Incorrectly labeled cosmetic",
      "Must complete voice therapy first",
      "Insufficient documentation of dysphoria",
      "Provider out-of-network"
    ],
    "how_we_help": "We help you build a WPATH-consistent appeal explaining why surgery is required and how conservative treatments were insufficient.",
    "cta": "Start your voice surgery appeal.",
    "faq": [
      {
        "question": "Do I have to do voice therapy before surgery for coverage?",
        "answer": "Some insurers require it, but your appeal can explain what you’ve tried, how effective it was, and why surgery is still necessary."
      },
      {
        "question": "Is voice surgery really considered medically necessary?",
        "answer": "For many people, yes. It can significantly reduce dysphoria and safety risks. Your appeal should connect the surgery directly to your health and functioning."
      },
      {
        "question": "Should I talk about misgendering in my appeal?",
        "answer": "Yes. Explain how your voice leads to misgendering, harassment, or avoidance of daily activities, which supports medical necessity."
      }
    ],
    "evidence_snippets": [
      "Gender-affirming voice surgery can produce durable pitch changes and improved gender congruence.",
      "Patients often report reduced dysphoria and improved social comfort after voice surgery.",
      "When voice therapy alone is insufficient, surgery is an evidence-supported next step for some patients."
    ],
    "pubmed_search_terms": [
      "gender affirming voice surgery outcomes pitch",
      "vocal feminization surgery satisfaction transgender women",
      "voice surgery transgender patients quality of life"
    ]
  },
  "hrt-denial": {
    "slug": "hrt-denial",
    "title": "Appealing Hormone Therapy (HRT) Denials",
    "default_procedure": "Gender-Affirming Hormone Therapy",
    "default_condition": "Gender Dysphoria",
    "tagline": "When your doctor prescribes hormone therapy, denials can often be appealed.",
    "hero_h1": "Appeal Your Hormone Therapy Denial",
    "hero_subhead": "Denials often rely on outdated guidelines or incorrect coding.",
    "intro": "Hormone therapy denials often stem from coding errors, documentation issues, or outdated insurer requirements. A well-documented appeal can address these issues.",
    "common_denial_reasons": [
      "Not medically necessary",
      "Plan claims it doesn't cover hormone therapy",
      "Missing diagnosis codes (gender dysphoria ICD-10)",
      "Duration of therapy requirements"
    ],
    "how_we_help": "We help you fix coding issues, document dysphoria, and demonstrate clear medical necessity supported by WPATH and Endocrine Society guidelines.",
    "cta": "Start your HRT appeal.",
    "faq": [
      {
        "question": "Do I need a specific diagnosis code for HRT coverage?",
        "answer": "Often yes. Appeals are stronger when they clearly reference a diagnosis like gender dysphoria or gender incongruence plus your clinician's treatment plan."
      },
      {
        "question": "What if my plan says it doesn't cover gender-affirming hormones at all?",
        "answer": "Your appeal can argue that excluding medically necessary gender-affirming care is discriminatory and conflicts with current medical standards."
      },
      {
        "question": "Can I appeal dose or formulation changes they denied?",
        "answer": "Yes. Your appeal can explain why your current or requested dose and route are clinically appropriate and monitored by your provider."
      }
    ],
    "evidence_snippets": [
      "Your provider's prescription and documentation are the foundation of a strong HRT appeal.",
      "WPATH and Endocrine Society guidelines can be cited in appeals to support your provider's treatment plan.",
      "Proper diagnosis coding (ICD-10) is often key to successful hormone therapy appeals."
    ],
    "pubmed_search_terms": [
      "gender affirming hormone therapy mental health outcomes",
      "endocrine society clinical practice guideline gender dysphoria",
      "transgender hormone therapy quality of life"
    ],
    "alternatives": [
      "Generic formulations of estradiol and testosterone are often significantly cheaper and may have better coverage.",
      "Different delivery methods (pills vs patches vs injections) may have different coverage status with your insurer.",
      "GoodRx and similar discount programs can significantly reduce out-of-pocket costs for hormone prescriptions."
    ],
    "assistance_programs": [
      {
        "name": "Point of Pride HRT Access Fund",
        "url": "https://www.pointofpride.org/hrt-access-fund",
        "description": "Provides 18 months of HRT-related care including visits, labs, and prescriptions for qualifying trans individuals."
      },
      {
        "name": "FOLX HRT Care Fund",
        "url": "https://www.folxhealth.com/hrt-care-fund",
        "description": "Year-long grants covering hormone therapy, clinical visits, and lab work through FOLX telehealth."
      },
      {
        "name": "Plume (with Trans Lifeline discount)",
        "url": "https://getplume.co/",
        "description": "Telehealth HRT provider. Trans Lifeline members receive discounted rates. Accepts some insurance."
      },
      {
        "name": "GoodRx Prescription Savings",
        "url": "https://www.goodrx.com/",
        "description": "Free discount card that can significantly reduce costs for generic estradiol and testosterone at pharmacies."
      }
    ]
  },
  "puberty-blocker-denial": {
    "slug": "puberty-blocker-denial",
    "title": "Appealing Puberty Blocker Denials",
    "default_procedure": "Puberty Blockers (GnRH Analogues)",
    "default_condition": "Gender Dysphoria",
    "tagline": "When your provider prescribes puberty blockers, denials can often be appealed.",
    "hero_h1": "Appeal Your Puberty Blocker Denial",
    "hero_subhead": "Puberty blocker denials often require strong appeals with proper documentation.",
    "intro": "Insurers often deny puberty blockers due to age requirements, documentation issues, or outdated policies. Your appeal should focus on your provider's recommendations and clinical guidelines.",
    "common_denial_reasons": [
      "Considered experimental",
      "Age requirements",
      "Missing mental health documentation",
      "Plan exclusion for gender affirming care"
    ],
    "how_we_help": "We help you align documentation with WPATH and pediatric endocrine guidelines to overturn these denials.",
    "cta": "Start your puberty blocker appeal.",
    "faq": [
      {
        "question": "Are puberty blockers really evidence-based?",
        "answer": "Yes. Puberty blockers have been used for decades and are included in multiple professional guidelines for treating early puberty and gender dysphoria."
      },
      {
        "question": "Do we need a mental health evaluation for coverage?",
        "answer": "Most insurers want documentation of gender dysphoria and a mental health professional's support. Your appeal can highlight those records."
      },
      {
        "question": "Can we appeal if the plan has a blanket exclusion?",
        "answer": "You can still appeal and argue that excluding medically necessary gender-affirming care is discriminatory and conflicts with current medical standards. The success of these arguments often depends on who the plans regulator is."
      }
    ],
    "evidence_snippets": [
      "Your provider's documentation and treatment plan are essential for a successful puberty blocker appeal.",
      "Professional guidelines from WPATH and pediatric endocrine societies can be cited in your appeal.",
      "GnRH analogues have been used for decades for various conditions and are included in clinical guidelines."
    ],
    "pubmed_search_terms": [
      "puberty suppression gender dysphoria outcomes",
      "GnRH analogue treatment transgender youth",
      "guidelines puberty blockers gender incongruence"
    ],
    "alternatives": [
      "Different GnRH analogue formulations (monthly vs. 3-month vs. implant) may have different coverage status.",
      "Ask your provider about which specific medication has the best formulary status with your insurer."
    ],
    "assistance_programs": [
      {
        "name": "Lupron Depot-PED Copay Assistance",
        "url": "https://www.lupronpedpro.com/",
        "description": "Eligible commercially insured patients may pay as little as $10 per prescription. Max $4,000-$7,000/year benefit."
      },
      {
        "name": "Abbott Patient Assistance Foundation (Lupron)",
        "url": "https://www.rxassist.org/pap-info/company-detail?CmpId=1",
        "description": "Free Lupron Depot for patients experiencing financial difficulties who meet eligibility criteria."
      },
      {
        "name": "Endo Pharmaceuticals PAP (Supprelin LA)",
        "url": "https://www.supprelinla.com/",
        "description": "Patient assistance program providing free medication to eligible uninsured/underinsured patients."
      },
      {
        "name": "Point of Pride HRT Access Fund",
        "url": "https://www.pointofpride.org/hrt-access-fund",
        "description": "While primarily for HRT, may assist with gender-affirming care navigation for trans youth (18+)."
      }
    ]
  },
  "grs-denial": {
    "slug": "grs-denial",
    "title": "Appealing Gender-Affirming Genital Surgery Denials",
    "default_procedure": "Gender-Affirming Genital Surgery (GRS)",
    "default_condition": "Gender Dysphoria",
    "tagline": "When your provider recommends genital surgery, denials can often be appealed.",
    "hero_h1": "Appeal Your Genital Surgery Denial",
    "hero_subhead": "Insurers deny GRS using outdated, incorrect, or discriminatory criteria.",
    "intro": "Insurers frequently deny gender-affirming genital surgery coverage based on obsolete guidelines or arbitrary requirements. A strong appeal focuses on your provider's recommendations and WPATH criteria.",
    "common_denial_reasons": [
      "Considered cosmetic or elective",
      "Insufficient therapy letters",
      "Genital surgery exclusions",
      "Provider out-of-network or limited network"
    ],
    "how_we_help": "We help you document dysphoria, prior treatments, safety concerns, and World Professional Association for Transgender Health(WPATH) Standards of Care (SOC) criteria to strengthen your appeal.",
    "cta": "Start your genital surgery appeal.",
    "faq": [
      {
        "question": "Do I need to meet exact WPATH criteria to appeal?",
        "answer": "Your appeal can show how you meet or reasonably align with those criteria, and why additional gatekeeping isn’t clinically justified."
      },
      {
        "question": "Can I appeal exclusions that say genital surgery is never covered?",
        "answer": "You can argue that blanket exclusions conflict with current medical standards and may be discriminatory. Some plans reconsider after internal and external review."
      },
      {
        "question": "Should I discuss safety and mental health in my appeal?",
        "answer": "This is a personal choice, but explaining how surgery relates to your mental health, safety, and ability to function in daily life can be helpful."
      }
    ],
    "evidence_snippets": [
      "Your surgeon's and mental health provider's documentation are essential for a successful GRS appeal.",
      "WPATH Standards of Care criteria can be cited in appeals to counter arbitrary insurer requirements.",
      "Professional medical organization positions can be referenced to counter claims that GRS is elective or cosmetic."
    ],
    "pubmed_search_terms": [
      "gender affirming genital surgery outcomes quality of life",
      "vaginoplasty satisfaction transgender women mental health",
      "phalloplasty transgender men outcomes dysphoria"
    ]
  },
  "fertility-preservation-denial": {
    "slug": "fertility-preservation-denial",
    "title": "Appealing Fertility Preservation Denials",
    "default_procedure": "Fertility Preservation Prior to treatment",
    "default_condition": "Gender Dysphoria",
    "tagline": "Many insurers must cover this when medically indicated — appeals often win.",
    "hero_h1": "Appeal Your Fertility Preservation Denial",
    "hero_subhead": "Egg or sperm preservation before gender-affirming, oncology, and other care can be medically necessary.",
    "intro": "Fertility preservation is critical for many trans people before starting HRT or undergoing surgery. Insurers frequently deny coverage due to outdated or discriminatory policies.",
    "common_denial_reasons": [
      "Not medically necessary",
      "Considered elective",
      "Plan excludes fertility services generally",
      "Incorrect coding for gender-affirming context"
    ],
    "how_we_help": "We help you reframe the request as medically necessary and supported by major medical societies, not elective.",
    "cta": "Start your fertility preservation appeal.",
    "faq": [
      {
        "question": "Why should fertility preservation be covered?",
        "answer": "Gender-affirming treatments can affect fertility. Preserving eggs or sperm beforehand is a medically recommended way to keep future family-building options open."
      },
      {
        "question": "What if my plan excludes all fertility treatment?",
        "answer": "Your appeal can argue that preserving fertility before medically necessary treatment is different from elective fertility treatment and should be considered part of comprehensive care."
      },
      {
        "question": "Do guidelines actually support fertility counseling and preservation?",
        "answer": "Many guidelines recommend discussing fertility options before starting treatments that can reduce fertility, including HRT and oncology."
      }
    ],
    "evidence_snippets": [
      "Clinical guidelines recommend discussing and offering fertility preservation options before treatments that may impair fertility.",
      "Transgender individuals often regret loss of fertility options when this is not addressed prior to treatment.",
      "Fertility preservation in this context is preventive care related to medically necessary treatment, not purely elective fertility enhancement."
    ],
    "pubmed_search_terms": [
      "fertility preservation transgender individuals guidelines",
      "counseling fertility options before gender affirming hormones",
      "fertility preservation oncology analogy standard of care"
    ]
  },
  "glp1-denial": {
    "slug": "glp1-denial",
    "title": "Appealing GLP-1 Medication Denials",
    "default_procedure": "GLP-1 Medication (Ozempic, Wegovy, Mounjaro, etc.)",
    "tagline": "Weight and diabetes meds are not vanity drugs when they treat real disease.",
    "hero_h1": "Appeal Your GLP-1 Medication Denial",
    "hero_subhead": "Whether for diabetes or obesity, GLP-1s are often medically necessary — not optional extras.",
    "intro": "GLP-1 medications like semaglutide and tirzepatide are frequently denied because insurers say your diagnosis does not qualify, you have not tried enough alternatives, or your plan excludes weight-loss drugs entirely. But for many people with diabetes and obesity-related conditions, these medications are key to preventing serious complications.",
    "common_denial_reasons": [
      "Plan excludes weight-loss medications",
      "Patient does not meet BMI or comorbidity criteria",
      "Has not tried metformin or other oral agents first",
      "Dose or formulation not on formulary",
      "Off-label use not covered"
    ],
    "how_we_help": "We help you explain your medical history, prior treatments, and obesity or diabetes-related complications in a way that shows this medication is medically necessary, not cosmetic. We also help you respond to step-therapy requirements and plan exclusions.",
    "cta": "Start your GLP-1 appeal in a few minutes.",
    "faq": [
      {
        "question": "Can I appeal if my plan excludes weight-loss drugs?",
        "answer": "Yes. You can argue that your GLP-1 is treating serious health conditions like diabetes, sleep apnea, or cardiovascular risk rather than purely cosmetic weight loss. Your appeal can emphasize comorbidities, functional limits, and guideline support for using GLP-1s in high-risk patients."
      },
      {
        "question": "What if I have already tried other diabetes medications?",
        "answer": "List every medication you have tried, how long you used it, and what happened. If you had side effects, poor control, or complications, your appeal should connect those experiences to why a GLP-1 is now medically appropriate."
      },
      {
        "question": "Can I appeal if my A1c is not extremely high?",
        "answer": "Yes. Your appeal can highlight other risk factors like obesity, cardiovascular disease, kidney disease, or prior complications. GLP-1s are often used to reduce long-term risk, not only to fix very high A1c values."
      }
    ],
    "evidence_snippets": [
      "GLP-1 receptor agonists improve glycemic control and promote clinically meaningful weight loss in many patients with type 2 diabetes and obesity.",
      "Large outcome trials show some GLP-1 medications reduce cardiovascular events in people at high risk.",
      "Treating obesity and diabetes aggressively can prevent downstream complications such as heart disease, kidney failure, and disability."
    ],
    "pubmed_search_terms": [
      "GLP-1 receptor agonist cardiovascular outcomes trial",
      "semaglutide weight loss obesity randomized study",
      "tirzepatide type 2 diabetes glycemic control"
    ]
  },
  "migraine-med-denial": {
    "slug": "migraine-med-denial",
    "title": "Appealing Migraine Medication Denials",
    "default_procedure": "Migraine Medications (CGRP Inhibitors, Gepants, Triptans)",
    "tagline": "When migraines steal your life, treatment is not optional.",
    "hero_h1": "Appeal Your Migraine Medication Denial",
    "hero_subhead": "CGRP meds, gepants, and triptans are often denied until you push back.",
    "intro": "Newer migraine medications are frequently denied as too expensive, not medically necessary, or reserved for people who have failed a long list of older drugs. Even older triptans may be limited to a tiny number of pills per month. A good appeal tells your story clearly and aligns it with headache guidelines.",
    "common_denial_reasons": [
      "Must fail multiple older preventive medications first",
      "Quantity limits on acute migraine medications",
      "Condition not documented as chronic or severe enough",
      "Off-label use or non-formulary medication"
    ],
    "how_we_help": "We help you explain how often you have migraines, how they affect work and daily life, which medications you have tried before, and why your prescriber chose this treatment. We turn that into a structured appeal that speaks the insurer's language.",
    "cta": "Start your migraine appeal now.",
    "faq": [
      {
        "question": "What should I include about my migraine history?",
        "answer": "Include how many days per month you have headaches, how many are disabling, what symptoms you experience, and how they affect work, school, or caregiving. If you have an official diagnosis of chronic migraine, make sure that is clearly stated."
      },
      {
        "question": "How do I respond to step-therapy requirements?",
        "answer": "Your appeal should list all preventives and acute medications you have already tried, including side effects and treatment failures. If a required medication is unsafe or inappropriate for you, your doctor can explain why it should be skipped."
      },
      {
        "question": "Can I appeal quantity limits on triptans or gepants?",
        "answer": "Yes. You can appeal by showing how many migraines you actually have per month, how you currently ration medication, and how inadequate quantities lead to ER visits, urgent care, or missed work."
      }
    ],
    "evidence_snippets": [
      "CGRP-targeting therapies reduce monthly migraine days and improve quality of life in patients with episodic and chronic migraine.",
      "Effective migraine prevention can reduce the need for emergency visits and hospitalizations.",
      "Treating migraine adequately lowers disability and improves work productivity and daily functioning."
    ],
    "pubmed_search_terms": [
      "calcitonin gene related peptide monoclonal antibody migraine trial",
      "gepants acute migraine randomized controlled",
      "chronic migraine prevention guidelines"
    ]
  },
  "asthma-biologic-denial": {
    "slug": "asthma-biologic-denial",
    "title": "Appealing Asthma Biologic Denials",
    "default_procedure": "Severe Asthma Biologic (Dupilumab, Omalizumab, etc.)",
    "tagline": "For severe asthma, biologics can be the difference between stability and the ICU.",
    "hero_h1": "Appeal Your Asthma Biologic Denial",
    "hero_subhead": "If inhalers and steroids are not enough, insurers should not stand in the way of the next step.",
    "intro": "Biologic medications for severe asthma, such as omalizumab, dupilumab, and others, are often denied because insurers say you have not met exact lab criteria, have not failed enough inhalers, or your asthma is not severe enough. These denials ignore how dangerous uncontrolled asthma can be.",
    "common_denial_reasons": [
      "Does not meet blood eosinophil or IgE thresholds",
      "Insufficient trial of high-dose inhaled corticosteroids and other controllers",
      "Asthma not documented as severe or uncontrolled",
      "Non-formulary biologic requested when a different one is preferred"
    ],
    "how_we_help": "We help you explain your asthma history, ER visits, oral steroid bursts, and test results so that an appeal clearly shows you meet guideline-based criteria for a biologic and that ongoing uncontrolled asthma is unsafe and costly.",
    "cta": "Start your asthma biologic appeal.",
    "faq": [
      {
        "question": "What counts as severe or uncontrolled asthma in an appeal?",
        "answer": "Frequent symptoms, night awakenings, multiple ER or urgent care visits, hospitalizations, or repeated steroid bursts are all signs of uncontrolled asthma. Your appeal should list these events and any limitations on daily activities."
      },
      {
        "question": "Do I need specific lab results for a biologic?",
        "answer": "Many biologics require lab values such as eosinophil counts or IgE levels. If you have those results, include them and have your doctor explain how they match the criteria. If results are borderline, your doctor can still explain why treatment is appropriate."
      },
      {
        "question": "Can I appeal if the insurer wants me to use a different biologic?",
        "answer": "Yes. Your clinician can explain why the prescribed biologic is the best choice for you, based on your phenotype, comorbidities, prior response, or side effects with others."
      }
    ],
    "evidence_snippets": [
      "Biologic therapies for severe asthma reduce exacerbation rates and oral steroid use in appropriately selected patients.",
      "Uncontrolled asthma is associated with frequent ER visits, hospitalizations, and impaired quality of life.",
      "Guidelines recommend escalation to biologic therapy when high-dose inhaled therapies do not adequately control disease."
    ],
    "pubmed_search_terms": [
      "severe asthma biologic therapy randomized trial",
      "omalizumab dupilumab mepolizumab exacerbation reduction",
      "GINA guideline severe asthma biologics"
    ]
  },
  "eczema-biologic-denial": {
    "slug": "eczema-biologic-denial",
    "title": "Appealing Eczema Biologic Denials",
    "default_procedure": "Biologic or Targeted Therapy for Atopic Dermatitis",
    "tagline": "Severe eczema is not just dry skin — it is a serious inflammatory disease.",
    "hero_h1": "Appeal Your Eczema Biologic Denial",
    "hero_subhead": "When topical creams fail, insurers often fight advanced therapies. You can fight back.",
    "intro": "For moderate-to-severe atopic dermatitis, biologic drugs and targeted therapies can dramatically reduce itching, skin breakdown, and infections. Insurers frequently deny them as too expensive, not medically necessary, or not tried long enough after topical treatments.",
    "common_denial_reasons": [
      "Topical therapies and phototherapy not tried long enough",
      "Disease severity not documented as moderate-to-severe",
      "Non-formulary drug requested when another is preferred",
      "Off-label dosing or age not covered"
    ],
    "how_we_help": "We help you tell the story of your eczema: how much of your body is affected, how often your skin flares, any infections or hospital visits, and what treatments you have already tried. We structure this into an appeal that aligns with dermatology guidelines.",
    "cta": "Start your eczema biologic appeal.",
    "faq": [
      {
        "question": "How do I show that my eczema is severe enough?",
        "answer": "Describe how many areas of your body are affected, how often your skin cracks or bleeds, any infections or hospital visits, and how itching disrupts sleep, work, or school. Dermatology notes and photographs can also help demonstrate severity."
      },
      {
        "question": "Do I have to fail every cream and phototherapy first?",
        "answer": "Not always. Your appeal can explain what you have already used, why some treatments were not tolerated or practical, and why moving to a biologic is now appropriate based on guidelines and your dermatologist's judgment."
      },
      {
        "question": "Can children or adolescents be covered for eczema biologics?",
        "answer": "Yes, many biologics have pediatric indications. Your appeal should note the patient's age, prior therapies, pediatric dosing recommendations, and the impact of uncontrolled eczema on growth, sleep, and development."
      }
    ],
    "evidence_snippets": [
      "Biologic therapies for atopic dermatitis improve skin clearance, reduce itching, and enhance quality of life compared to standard topical treatments alone.",
      "Uncontrolled atopic dermatitis is associated with sleep disturbance, infections, and significant psychosocial burden.",
      "Guidelines support escalating to systemic or biologic treatments when topical therapies are insufficient for moderate-to-severe disease."
    ],
    "pubmed_search_terms": [
      "dupilumab atopic dermatitis randomized controlled trial",
      "systemic therapy moderate severe atopic dermatitis guidelines",
      "quality of life atopic dermatitis biologic therapy"
    ]
  },
  "insulin-pump-cgm-denial": {
    "slug": "insulin-pump-cgm-denial",
    "title": "Appealing Insulin Pump and CGM Denials",
    "default_procedure": "Insulin Pump or Continuous Glucose Monitor",
    "tagline": "For many people with diabetes, diabetes tech is not a luxury — it is survival.",
    "hero_h1": "Appeal Your Insulin Pump or CGM Denial",
    "hero_subhead": "Insurers often set narrow criteria for diabetes technology. Your real-world data can change their minds.",
    "intro": "Insulin pumps and continuous glucose monitors (CGMs) help people with diabetes keep blood sugar in a safer range and avoid life-threatening highs and lows. Insurers often deny them for not meeting strict eligibility rules, being on the wrong diagnosis code, or preferring older, less effective approaches.",
    "common_denial_reasons": [
      "Diagnosis code or type of diabetes does not meet policy criteria",
      "Not enough documented episodes of hypoglycemia or hyperglycemia",
      "Failure to document multiple daily injections and frequent glucose testing",
      "Device not on the formulary or out-of-network supplier"
    ],
    "how_we_help": "We ask you questions to help provide information about A1c trends, episodes of severe lows or highs, and prior treatment history so your appeal shows why a pump or CGM is medically necessary, not just convenient.",
    "cta": "Start your insulin pump or CGM appeal.",
    "faq": [
      {
        "question": "What information should I include from my glucose records?",
        "answer": "Include examples of frequent lows, wide swings, or persistent high readings despite following your regimen. Downloaded reports from meters or existing CGMs can show patterns that justify advanced technology."
      },
      {
        "question": "Can people with type 2 diabetes ever get pumps or CGMs covered?",
        "answer": "Yes. Many policies allow coverage when there is intensive insulin use, high risk of hypoglycemia, or complications. Your appeal should highlight these factors and show why structured finger-stick testing is insufficient."
      },
      {
        "question": "What if the insurer wants a different brand of device?",
        "answer": "You can appeal by having your prescriber explain why a specific device is medically preferable for you, such as integration with your pump, alarm features, vision or dexterity issues, or prior problems with other brands."
      }
    ],
    "evidence_snippets": [
      "Continuous glucose monitoring reduces time spent in hypoglycemia and improves overall glycemic control compared with traditional self-monitoring alone.",
      "Insulin pump therapy can improve flexibility and glycemic outcomes in selected patients, especially those with type 1 diabetes.",
      "Better glycemic control reduces the risk of long-term complications such as kidney disease, neuropathy, and retinopathy."
    ],
    "pubmed_search_terms": [
      "continuous glucose monitoring randomized trial hypoglycemia",
      "insulin pump therapy type 1 diabetes outcomes",
      "technology-assisted diabetes care quality of life"
    ]
  },
  "prosthetic-denial": {
    "slug": "prosthetic-denial",
    "title": "Appealing Prosthetic Limb Denials",
    "default_procedure": "Prosthetic Limb or Advanced Prosthetic Component",
    "tagline": "Mobility, independence, and work are not cosmetic goals.",
    "hero_h1": "Appeal Your Prosthetic Limb Denial",
    "hero_subhead": "When insurers push the cheapest option, you can push back with function and safety.",
    "intro": "People who use prosthetic limbs often face denials for new devices, replacements, or advanced components like microprocessor knees. Insurers may argue that a lower-level device is sufficient or that advanced features are not medically necessary.",
    "common_denial_reasons": [
      "Cheaper or more basic prosthetic considered adequate",
      "Replacement requested too soon according to policy",
      "Insufficient documentation of activity level or goals",
      "Advanced components labeled as convenience or luxury"
    ],
    "how_we_help": "We help you describe your daily activities, work demands, fall risks, and medical conditions in a way that shows why the prescribed device level is necessary for safe ambulation and independence.",
    "cta": "Start your prosthetic appeal.",
    "faq": [
      {
        "question": "How do I show that I need an advanced component?",
        "answer": "Describe your typical day, walking surfaces, job tasks, and any history of falls or near-falls. Your prosthetist can explain why a basic device cannot safely support those activities and how advanced components reduce risk."
      },
      {
        "question": "What if my insurer says my current prosthetic should last longer?",
        "answer": "Your appeal can include documentation of wear, fit problems, changes in limb shape, or activity level increases that make a replacement medically necessary even if arbitrary time limits have not been reached."
      },
      {
        "question": "Can I appeal if they only approve a device suited for limited indoor walking?",
        "answer": "Yes. If you need to walk outdoors, at work, or on uneven surfaces, your prosthetist can explain that your functional level requires a device designed for that activity, not a purely basic indoor limb."
      }
    ],
    "evidence_snippets": [
      "Appropriate prosthetic prescription is associated with improved mobility, reduced fall risk, and better participation in work and community life.",
      "Under-prescription of prosthetic technology can increase long-term costs by contributing to falls, injuries, and loss of independence.",
      "Prosthetic selection should be based on functional level, comorbidities, and goals rather than lowest upfront cost."
    ],
    "pubmed_search_terms": [
      "prosthetic limb functional outcomes microprocessor knee",
      "amputee mobility falls risk prosthesis",
      "cost effectiveness advanced prosthetic components"
    ]
  },
  "hearing-aid-denial": {
    "slug": "hearing-aid-denial",
    "title": "Appealing Hearing Aid and Cochlear Implant Denials",
    "default_procedure": "Hearing Aids or Cochlear Implant",
    "tagline": "Communication is a health need, not a luxury.",
    "hero_h1": "Appeal Your Hearing Aid or Cochlear Implant Denial",
    "hero_subhead": "Even when policies are restrictive, you may still be able to win coverage for medically necessary hearing devices.",
    "intro": "Many plans exclude hearing aids entirely or only cover very limited devices for certain ages. Cochlear implants may be denied for not meeting audiologic criteria. Appeals can focus on the health, safety, and developmental impact of untreated hearing loss.",
    "common_denial_reasons": [
      "Plan excludes hearing aids as a benefit",
      "Hearing loss not severe enough by plan criteria",
      "Age limits or frequency limits on devices",
      "Cochlear implant criteria not fully met"
    ],
    "how_we_help": "We help you present your reports, speech and language impacts, workplace communication needs, safety concerns, and developmental risks so your appeal shows why a hearing device is medically necessary.",
    "cta": "Start your hearing device appeal.",
    "faq": [
      {
        "question": "Can I appeal if my plan excludes hearing aids?",
        "answer": "You can still appeal by emphasizing that untreated hearing loss affects safety, mental health, and ability to work or learn. Success varies by plan, but a strong appeal can sometimes lead to exceptions or partial coverage."
      },
      {
        "question": "What documentation should I include?",
        "answer": "Include audiograms, speech discrimination scores, notes from audiologists or ENT specialists, and descriptions of how hearing loss affects daily life, school, or work. For children, include information about speech and language development."
      },
      {
        "question": "What about cochlear implant denials?",
        "answer": "Your appeal should address each criterion in the policy, include updated audiology testing, and have your implant team explain why an implant is necessary to achieve functional hearing despite hearing aids."
      }
    ],
    "evidence_snippets": [
      "Untreated hearing loss is associated with social isolation, depression, and cognitive decline in adults.",
      "Early access to amplification or cochlear implantation improves language and educational outcomes in children with significant hearing loss.",
      "Hearing devices can reduce safety risks related to environmental awareness, such as hearing alarms and traffic."
    ],
    "pubmed_search_terms": [
      "hearing aid outcomes quality of life adult hearing loss",
      "cochlear implant speech language development children",
      "hearing loss cognitive decline association"
    ]
  },
  "genetic-testing-denial": {
    "slug": "genetic-testing-denial",
    "title": "Appealing Genetic Testing Denials",
    "default_procedure": "Genetic or Genomic Testing",
    "tagline": "Genetic answers can change treatment, screening, and family planning.",
    "hero_h1": "Appeal Your Genetic Testing Denial",
    "hero_subhead": "When testing could change your care, insurers should not dismiss it as unnecessary.",
    "intro": "Genetic and genomic tests are often denied as experimental, not medically necessary, or not covered for your specific indication. For many conditions, however, test results directly affect treatment choices, cancer screening, or family risk.",
    "common_denial_reasons": [
      "Test considered experimental or investigational",
      "Patient does not meet narrow family history criteria",
      "Gene panel larger than policy allows",
      "Testing ordered by non-specialist provider"
    ],
    "how_we_help": "We help you show how test results will change management, summarize relevant family history, and map your situation to guideline-based indications for testing.",
    "cta": "Start your genetic testing appeal.",
    "faq": [
      {
        "question": "How do I show that genetic testing will change my care?",
        "answer": "Have your clinician explain how positive, negative, or uncertain results would affect medication choice, surveillance imaging, surgery, or recommendations for relatives. Appeals are strongest when the link between results and action is clear."
      },
      {
        "question": "What if my family history is complicated or incomplete?",
        "answer": "Your appeal can still describe known relatives with relevant cancers or conditions, and explain any barriers to obtaining more information. Genetic counselors are skilled at working with incomplete pedigrees and can support testing when risk is still elevated."
      },
      {
        "question": "Can I appeal broad gene panel denials?",
        "answer": "Yes. Your clinician or genetic counselor can justify why a panel is more appropriate than single-gene testing, especially when multiple syndromes could explain your or your family's history."
      }
    ],
    "evidence_snippets": [
      "Genetic testing for hereditary cancer syndromes can guide screening, prophylactic surgery, and targeted therapy.",
      "Identifying pathogenic variants allows cascade testing of at-risk relatives, enabling early detection and prevention.",
      "Professional guidelines support genetic evaluation when personal or family history suggests an inherited risk."
    ],
    "pubmed_search_terms": [
      "hereditary cancer genetic testing guidelines BRCA Lynch",
      "clinical utility multigene panel testing oncology",
      "cascade genetic testing prevention outcomes"
    ]
  },
  "pet-scan-denial": {
    "slug": "pet-scan-denial",
    "title": "Appealing PET Scan Denials",
    "default_procedure": "Positron Emission Tomography (PET) Scan",
    "tagline": "When staging or restaging cancer, the right scan matters.",
    "hero_h1": "Appeal Your PET Scan Denial",
    "hero_subhead": "PET scans are often key for cancer staging and treatment decisions — and often denied on cost grounds.",
    "intro": "PET scans are widely used in oncology and some neurologic and cardiac conditions, but insurers frequently deny them as not medically necessary, outside of policy indications, or unnecessary compared with CT alone.",
    "common_denial_reasons": [
      "PET not on policy list for this cancer type or stage",
      "Alternative imaging considered sufficient",
      "Repeat PET within restricted time window",
      "Non-oncologic use considered experimental"
    ],
    "how_we_help": "We help explain how PET results will affect treatment decisions, show that your situation matches guideline-based indications, and address concerns about repeated or off-label use.",
    "cta": "Start your PET scan appeal.",
    "faq": [
      {
        "question": "When is a PET scan usually considered medically necessary?",
        "answer": "Many cancer guidelines recommend PET for initial staging, assessing treatment response, or evaluating suspected recurrence in specific cancers. Your appeal should reference those guidelines and your exact clinical question."
      },
      {
        "question": "Can I appeal a denial for a repeat PET scan?",
        "answer": "Yes. Your appeal can explain why new symptoms, lab changes, or treatment milestones make a repeat scan important now, and how results will alter the treatment plan."
      },
      {
        "question": "What about PET scans for non-cancer conditions?",
        "answer": "Some neurologic or cardiac PET scans have established roles. Your specialist can cite evidence and explain why PET, and not another test, is needed for accurate diagnosis or risk assessment."
      }
    ],
    "evidence_snippets": [
      "PET imaging improves staging accuracy in many cancers, which can change surgical and systemic treatment decisions.",
      "PET scans are useful in assessing metabolic response to therapy and detecting residual or recurrent disease.",
      "Guidelines specify indications where PET is preferred or recommended over conventional imaging alone."
    ],
    "pubmed_search_terms": [
      "PET CT oncology staging treatment decisions",
      "FDG PET response assessment cancer outcomes",
      "PET indications guideline tumor staging"
    ]
  },
  "bariatric-surgery-denial": {
    "slug": "bariatric-surgery-denial",
    "title": "Appealing Bariatric Surgery Denials",
    "default_procedure": "Metabolic or Bariatric Surgery",
    "default_condition": "Obesity",
    "tagline": "Bariatric surgery treats a disease — it is not a cosmetic shortcut.",
    "hero_h1": "Appeal Your Bariatric Surgery Denial",
    "hero_subhead": "When obesity is harming your health, surgery may be the evidence-based treatment.",
    "intro": "Bariatric surgery is one of the most effective treatments for severe obesity and related conditions, yet many plans deny coverage based on BMI thresholds, documentation technicalities, or blanket exclusions for weight-loss procedures.",
    "common_denial_reasons": [
      "BMI or comorbidity criteria not met on paper",
      "Insufficient documentation of supervised weight-loss attempts",
      "Plan excludes bariatric surgery as a benefit",
      "Required evaluations or classes not documented"
    ],
    "how_we_help": "We help you gather weight history, comorbid conditions, prior supervised programs, and multidisciplinary evaluations to show that bariatric surgery is medically necessary and consistent with major guidelines.",
    "cta": "Start your bariatric surgery appeal.",
    "faq": [
      {
        "question": "What if I have not completed a long supervised diet program?",
        "answer": "Your appeal can explain attempts you have made to lose weight, including structured and unstructured efforts, and why further delay would worsen health risks. Your surgeon can also explain how rigid program requirements may not reflect current evidence."
      },
      {
        "question": "How do I document obesity-related health problems?",
        "answer": "Include diagnoses such as diabetes, sleep apnea, hypertension, fatty liver disease, joint disease, and any hospitalizations or limitations caused by weight. Laboratory results and sleep studies can be helpful."
      },
      {
        "question": "Can I appeal a plan exclusion on bariatric surgery?",
        "answer": "You can argue that excluding evidence-based treatment for a chronic disease is inconsistent with modern medical standards. Success depends on plan type and state law, but strong appeals sometimes lead employers or plans to make exceptions."
      }
    ],
    "evidence_snippets": [
      "Bariatric surgery leads to substantial and sustained weight loss and can induce remission of type 2 diabetes in many patients.",
      "Surgery reduces long-term risks of cardiovascular disease, mortality, and obesity-related complications compared with non-surgical management for eligible patients.",
      "Professional societies consider bariatric surgery medically necessary treatment for selected individuals with severe obesity and comorbid conditions."
    ],
    "pubmed_search_terms": [
      "bariatric surgery long term outcomes mortality",
      "gastric bypass diabetes remission randomized",
      "metabolic surgery guidelines obesity treatment"
    ]
  },
  "substance-use-treatment-denial": {
    "slug": "substance-use-treatment-denial",
    "title": "Appealing Substance Use Treatment Denials",
    "default_procedure": "Substance Use Disorder Treatment (Inpatient, IOP, MAT)",
    "default_condition": "Substance Use Disorder",
    "tagline": "Addiction is a chronic medical condition — treatment should be covered like any other.",
    "hero_h1": "Appeal Your Substance Use Treatment Denial",
    "hero_subhead": "When your life or your loved one's life is at stake, coverage denials are not acceptable.",
    "intro": "Detox, rehab, medication-assisted treatment, and intensive outpatient programs for substance use disorders are often denied or cut short, even though mental health parity laws require comparable coverage to medical conditions.",
    "common_denial_reasons": [
      "Lower level of care deemed sufficient",
      "Length of stay considered longer than medically necessary",
      "Medication-assisted treatment limited or not covered",
      "Plan claims no benefit for residential or certain program types"
    ],
    "how_we_help": "We help you explain the relapse risk, withdrawal history, co-occurring conditions, and safety concerns so your appeal shows why the recommended level of care and duration are medically necessary.",
    "cta": "Start your substance use treatment appeal.",
    "faq": [
      {
        "question": "How does mental health parity help my appeal?",
        "answer": "Parity laws generally require that insurers use comparable criteria for mental health and substance use treatment as for medical care. Your appeal can point out if stricter limits or different rules are being applied to addiction treatment."
      },
      {
        "question": "What should my provider include in their letter?",
        "answer": "They should describe your diagnosis, prior treatment attempts, overdose history, medical and psychiatric comorbidities, home environment, and why a specific level of care (inpatient, residential, IOP, or MAT) is needed now."
      },
      {
        "question": "Can I appeal denial of medication-assisted treatment?",
        "answer": "Yes. Your appeal can explain how medications like buprenorphine, methadone, or naltrexone reduce overdose risk and support recovery, and why discontinuing or restricting them is dangerous."
      }
    ],
    "evidence_snippets": [
      "Medication-assisted treatment for opioid use disorder reduces overdose deaths and improves retention in care.",
      "Higher levels of care are often required after relapse, overdose, or failed lower-intensity treatment.",
      "Parity regulations support equitable coverage for substance use disorder treatment compared with other medical conditions."
    ],
    "pubmed_search_terms": [
      "medication assisted treatment opioid use disorder mortality",
      "inpatient versus outpatient substance use treatment outcomes",
      "mental health parity substance use insurance coverage"
    ]
  },
  "emergency-room-denial": {
    "slug": "emergency-room-denial",
    "title": "Appealing Emergency Room Visit Denials",
    "default_procedure": "Emergency Department Visit",
    "tagline": "If it felt like an emergency at the time, the law is usually on your side.",
    "hero_h1": "Appeal Your ER Visit Denial",
    "hero_subhead": "Insurers often second-guess emergencies after the fact — appeals can force them to apply the prudent layperson standard.",
    "intro": "Some insurers deny emergency department claims by saying your condition was not an emergency after all. This ignores the reality that patients must decide based on symptoms in the moment, not final diagnoses.",
    "common_denial_reasons": [
      "Condition judged non-emergent in hindsight",
      "Care could have been provided at urgent care or primary care",
      "Out-of-network emergency facility charges denied",
      "Observation vs. inpatient status disputes tied to the ER visit"
    ],
    "how_we_help": "We help you describe what you were experiencing before you went to the ER, connect those symptoms to reasonable fears of serious harm, and point to laws that require insurers to use the prudent layperson standard.",
    "cta": "Start your ER visit appeal.",
    "faq": [
      {
        "question": "What is the prudent layperson standard?",
        "answer": "It is a legal standard that requires emergency coverage if a reasonable person with your symptoms would think they might have a serious medical problem, even if the final diagnosis turns out to be minor."
      },
      {
        "question": "What should I include in my appeal about the ER visit?",
        "answer": "Describe your symptoms before going to the ER, any prior calls to nurse lines or doctors, why you thought it was serious, and what treatments or tests were done there. Include the ER doctor's notes if possible."
      },
      {
        "question": "Can I appeal out-of-network emergency bills?",
        "answer": "Yes. Many laws require emergency care to be covered at in-network cost sharing even if the hospital or clinician is out of network. Your appeal can reference these protections and ask for a corrected claim."
      }
    ],
    "evidence_snippets": [
      "Emergency patients must make care decisions without knowing the final diagnosis, which is why coverage rules focus on presenting symptoms.",
      "Delays in seeking emergency care can worsen outcomes in conditions such as heart attack, stroke, and sepsis.",
      "Regulations generally prohibit insurers from denying emergency claims solely because the final diagnosis appears non-urgent."
    ],
    "pubmed_search_terms": [
      "prudent layperson standard emergency department insurance",
      "emergency room visit denial insurance appeals",
      "delay in seeking emergency care outcomes"
    ]
  },
  "ambulance-transport-denial": {
    "slug": "ambulance-transport-denial",
    "title": "Appealing Ambulance Transport Denials",
    "default_procedure": "Ground or Air Ambulance Transport",
    "tagline": "If it was not safe to drive, ambulance care was not optional.",
    "hero_h1": "Appeal Your Ambulance Bill Denial",
    "hero_subhead": "Ambulance denials often ignore the safety and urgency that existed at the time.",
    "intro": "Ambulance rides are frequently denied as not medically necessary or out-of-network, leaving patients with large bills. Appeals should focus on why you could not safely travel by private car and how the situation met emergency criteria.",
    "common_denial_reasons": [
      "Transport judged non-emergent",
      "Patient considered stable for private vehicle",
      "Out-of-network ambulance provider",
      "No prior authorization"
    ],
    "how_we_help": "We help you explain the symptoms, risks, and scene circumstances that made ambulance transport the only safe option, and we help you reference protections for emergency transport where they apply.",
    "cta": "Start your ambulance transport appeal.",
    "faq": [
      {
        "question": "What counts as medically necessary ambulance transport?",
        "answer": "Situations where you could worsen or harm yourself by traveling in a private vehicle, such as chest pain, breathing difficulty, altered mental status, severe injuries, or when monitoring and interventions are needed during transport."
      },
      {
        "question": "Can I appeal if the ambulance was out of network?",
        "answer": "Yes. Your appeal can argue that in an emergency you could not shop for in-network transport and that emergency protections should limit your financial responsibility."
      },
      {
        "question": "Should I include the EMS run sheet?",
        "answer": "If you can obtain it, yes. The run sheet documents your vital signs, symptoms, and treatments in the field, which can strongly support medical necessity."
      }
    ],
    "evidence_snippets": [
      "EMS transport provides monitoring and interventions en route that are not available in private vehicles.",
      "Timely ambulance transport can improve outcomes in conditions such as stroke, trauma, and acute coronary syndromes.",
      "Emergency care protections are intended to prevent financial penalties for calling 911 in good faith."
    ],
    "pubmed_search_terms": [
      "emergency medical services transport outcomes",
      "ambulance use medical necessity criteria",
      "out of network ambulance surprise billing"
    ]
  },
  "glp1-denial-semaglutide-ozempic": {
    "slug": "glp1-denial-semaglutide-ozempic",
    "title": "Appealing Ozempic (Semaglutide) Denials",
    "default_procedure": "Ozempic (Semaglutide)",
    "default_condition": "Type 2 Diabetes",
    "tagline": "Ozempic treats more than blood sugar — it helps prevent serious complications.",
    "hero_h1": "Appeal Your Ozempic Denial",
    "hero_subhead": "If your clinician prescribed Ozempic, chances are there’s a strong medical reason.",
    "intro": "Ozempic (semaglutide) is often denied because insurers say your A1c is not high enough, you have not failed enough other medications, or they consider it too expensive. But Ozempic can be medically necessary to control diabetes, reduce complications, and address obesity-related risk.",
    "common_denial_reasons": [
      "Not meeting A1c or diagnosis criteria for coverage",
      "Plan requires failure of multiple cheaper diabetes medications first",
      "Dose or pen strength not on formulary",
      "Use for weight reduction considered non-covered"
    ],
    "how_we_help": "We help you list prior medications, side effects, comorbidities, and complication risks so your appeal shows why Ozempic is the right next step—not a cosmetic option.",
    "cta": "Start your Ozempic appeal.",
    "faq": [
      {
        "question": "What should I include about my diabetes history?",
        "answer": "Include your A1c trend, episodes of highs and lows, other conditions like kidney disease, neuropathy, or sleep apnea, and all medications you have tried. Make it clear that Ozempic is part of preventing further damage, not just lowering a number on paper."
      },
      {
        "question": "Can I appeal if my insurer says I must stay on older drugs?",
        "answer": "Yes. Your appeal can explain how you used those medications, why they did not work well enough or caused side effects, and why your prescriber chose Ozempic instead."
      }
    ],
    "evidence_snippets": [
      "Semaglutide improves glycemic control and promotes clinically meaningful weight loss in adults with type 2 diabetes.",
      "GLP-1 receptor agonists like semaglutide have shown cardiovascular benefit in high-risk patients.",
      "Aggressive management of type 2 diabetes reduces long-term complications such as kidney failure, neuropathy, and cardiovascular events."
    ],
    "pubmed_search_terms": [
      "semaglutide Ozempic type 2 diabetes cardiovascular outcomes",
      "semaglutide GLP-1 receptor agonist glycemic control",
      "GLP-1 agonist weight loss diabetes complications"
    ],
    "assistance_programs": [
      {
        "name": "Ozempic Savings Card",
        "url": "https://www.ozempic.com/savings-and-resources/save-on-ozempic.html",
        "description": "Pay as little as $25/month for up to 48 months with commercial insurance. Not for government programs."
      },
      {
        "name": "NovoCare - Ozempic",
        "url": "https://www.novocare.com/diabetes/products/ozempic.html",
        "description": "Savings offers, patient assistance program for eligible uninsured patients, and support resources."
      },
      {
        "name": "Novo Nordisk Patient Assistance Program",
        "url": "https://www.novocare.com/diabetes/help-with-costs/pap.html",
        "description": "Free medication for qualifying patients at or below 400% federal poverty level without insurance."
      }
    ]
  },
  "glp1-denial-semaglutide-wegovy": {
    "slug": "glp1-denial-semaglutide-wegovy",
    "title": "Appealing Wegovy (Semaglutide) Denials",
    "default_procedure": "Wegovy (Semaglutide for Obesity)",
    "default_condition": "Obesity",
    "tagline": "Wegovy is obesity treatment, not vanity medicine.",
    "hero_h1": "Appeal Your Wegovy Denial",
    "hero_subhead": "When weight is damaging your health, Wegovy can be medically necessary care.",
    "intro": "Wegovy is frequently denied because plans exclude weight-loss drugs, require very specific BMI thresholds, or ignore obesity-related complications. Appeals can reframe Wegovy as treatment for a chronic disease that is harming your health, not a cosmetic choice.",
    "common_denial_reasons": [
      "Plan excludes anti-obesity medications entirely",
      "BMI criteria or comorbidity rules not met on paper",
      "Insufficient documentation of prior weight-loss attempts",
      "Dose strength not on formulary"
    ],
    "how_we_help": "We help you present your BMI history, obesity-related conditions, prior supervised and unsupervised weight-loss efforts, and functional limitations to show Wegovy is medically necessary obesity treatment.",
    "cta": "Start your Wegovy appeal.",
    "faq": [
      {
        "question": "How do I show Wegovy is more than cosmetic?",
        "answer": "Describe specific health issues—such as diabetes, sleep apnea, hypertension, joint damage, or fatty liver—and how weight worsens them. Explain how weight affects your ability to work, parent, or perform daily tasks."
      },
      {
        "question": "What if my plan says it never covers weight-loss drugs?",
        "answer": "You can still appeal by emphasizing that obesity is a chronic disease and Wegovy is evidence-based treatment for high-risk patients. Some employers or plans grant exceptions when the medical risk is clear."
      }
    ],
    "evidence_snippets": [
      "Once-weekly semaglutide for obesity results in substantial and sustained weight loss compared with lifestyle interventions alone.",
      "Weight reduction in people with obesity improves blood pressure, glycemic control, and cardiovascular risk factors.",
      "Obesity is recognized as a chronic disease requiring long-term management, not a short-term cosmetic issue."
    ],
    "pubmed_search_terms": [
      "semaglutide Wegovy obesity randomized controlled trial",
      "GLP-1 receptor agonist weight loss cardiovascular risk",
      "pharmacologic treatment obesity guidelines semaglutide"
    ],
    "assistance_programs": [
      {
        "name": "Wegovy Savings Card",
        "url": "https://www.wegovy.com/coverage-and-savings/save-on-wegovy.html",
        "description": "Pay as little as $0/month with commercial insurance coverage (up to $225 off per fill). Not for government programs."
      },
      {
        "name": "NovoCare - Wegovy",
        "url": "https://www.novocare.com/obesity/products/wegovy/savings-offer.html",
        "description": "Savings offers and support for Wegovy patients, including $349/month self-pay option."
      },
      {
        "name": "NovoCare Pharmacy",
        "url": "https://www.novocare.com/eligibility/wegovy-savings-card.html",
        "description": "Home delivery option for self-pay patients with access to savings programs."
      }
    ]
  },
  "glp1-denial-tirzepatide-mounjaro": {
    "slug": "glp1-denial-tirzepatide-mounjaro",
    "title": "Appealing Mounjaro (Tirzepatide) Denials",
    "default_procedure": "Mounjaro (Tirzepatide for Type 2 Diabetes)",
    "default_condition": "Type 2 Diabetes",
    "tagline": "Tirzepatide is a powerful tool for high-risk diabetes, not an optional upgrade.",
    "hero_h1": "Appeal Your Mounjaro Denial",
    "hero_subhead": "If prior regimens failed, denying Mounjaro can be unsafe and short-sighted.",
    "intro": "Mounjaro is often denied because it is newer, more expensive, and requires strict criteria. Insurers may demand failure of multiple other drugs or limit use to narrow subsets of people with type 2 diabetes.",
    "common_denial_reasons": [
      "Not enough prior medication failures documented",
      "Use for weight reduction rather than documented diabetes",
      "Dose or titration schedule not on formulary",
      "Plan prefers a different GLP-1/GIP agent"
    ],
    "how_we_help": "We help you document your full diabetes regimen history, comorbidities, and any complications so your appeal shows why Mounjaro is clinically appropriate and not easily substituted.",
    "cta": "Start your Mounjaro appeal.",
    "faq": [
      {
        "question": "What makes Mounjaro medically necessary in my case?",
        "answer": "Explain your current A1c, prior therapies, side effects, weight-related risk, and any complications. Your prescriber can explain why tirzepatide’s mechanism and potency are especially helpful for your situation."
      },
      {
        "question": "Can I appeal if I am also hoping for weight loss benefits?",
        "answer": "Yes. You can acknowledge weight loss benefits while emphasizing that the primary goal is better diabetes control and reduced risk of cardiovascular and metabolic complications."
      }
    ],
    "evidence_snippets": [
      "Tirzepatide significantly lowers A1c and body weight in adults with type 2 diabetes compared with several existing therapies.",
      "Intensive glycemic control in high-risk patients reduces microvascular and, in some groups, macrovascular complications.",
      "Treatments that address both hyperglycemia and obesity can provide synergistic risk reduction."
    ],
    "pubmed_search_terms": [
      "tirzepatide Mounjaro type 2 diabetes randomized trial",
      "dual GIP GLP-1 agonist glycemic control weight",
      "tirzepatide cardiovascular risk factors outcomes"
    ],
    "assistance_programs": [
      {
        "name": "Mounjaro Savings Card",
        "url": "https://www.mounjaro.lilly.com/savings-resources",
        "description": "Pay as little as $25/month with commercial insurance coverage. Up to $150 off per fill."
      }
    ]
  },
  "glp1-denial-tirzepatide-zepbound": {
    "slug": "glp1-denial-tirzepatide-zepbound",
    "title": "Appealing Zepbound (Tirzepatide) Denials",
    "default_procedure": "Zepbound (Tirzepatide for Obesity)",
    "default_condition": "Obesity",
    "tagline": "Zepbound is intensive obesity medicine for high-risk patients, not a vanity drug.",
    "hero_h1": "Appeal Your Zepbound Denial",
    "hero_subhead": "When obesity is damaging your health, denying Zepbound can be dangerous.",
    "intro": "Zepbound is commonly denied because anti-obesity medications are excluded or tightly restricted. Appeals can connect Zepbound to concrete health outcomes: fewer complications, fewer hospitalizations, and better function.",
    "common_denial_reasons": [
      "Anti-obesity medications excluded from coverage",
      "BMI and comorbidity criteria not documented correctly",
      "Insufficient evidence of structured weight-loss attempts",
      "Dose or duration limits exceeded"
    ],
    "how_we_help": "We help you compile your BMI history, documented co-morbidities, prior weight-loss programs, and functional impairment so your appeal makes a strong medical case for Zepbound.",
    "cta": "Start your Zepbound appeal.",
    "faq": [
      {
        "question": "How do I document prior weight-loss attempts?",
        "answer": "List supervised programs, diets, medications, and lifestyle changes, including durations and outcomes. If weight was regained, note why, such as medication side effects or mobility limits."
      },
      {
        "question": "Can my doctor's letter make a difference?",
        "answer": "Yes. A concise letter linking Zepbound to reduction in concrete risks—such as diabetes progression, sleep apnea, or heart disease—can be very persuasive."
      },
      {
        "question": "What if my plan is switching to a different GLP-1 medication?",
        "answer": "If you're already stable on Zepbound and your insurer wants you to switch (e.g., CVS Caremark moving to Wegovy in mid-2025), you may have continuity of care rights. You can request a medical exception. Many states also have non-medical switching laws. See our continuity of care page for more information."
      }
    ],
    "evidence_snippets": [
      "Tirzepatide produces substantial weight loss in adults with obesity, often exceeding that of earlier agents.",
      "Weight loss improves cardiometabolic risk factors and can prevent or delay type 2 diabetes in high-risk individuals.",
      "Treating obesity as a chronic disease requires long-term strategies, including medications when appropriate."
    ],
    "pubmed_search_terms": [
      "tirzepatide obesity clinical trial weight loss",
      "pharmacologic treatment obesity tirzepatide",
      "anti-obesity medication cardiometabolic outcomes"
    ],
    "assistance_programs": [
      {
        "name": "Zepbound Savings Card",
        "url": "https://www.zepbound.lilly.com/coverage-savings",
        "description": "Pay as little as $25/month with commercial insurance coverage, or up to $569 off without coverage. Not for government insurance."
      },
      {
        "name": "LillyDirect - Zepbound",
        "url": "https://www.lilly.com/lillydirect/medicines/zepbound",
        "description": "Order Zepbound vials direct from Lilly for $299/month (self-pay option)."
      }
    ]
  },

  "asthma-biologic-denial-dupilumab": {
    "slug": "asthma-biologic-denial-dupilumab",
    "title": "Appealing Dupixent (Dupilumab) Asthma Denials",
    "default_procedure": "Dupixent for Severe Asthma",
    "default_condition": "Severe Asthma",
    "tagline": "Dupixent can calm type 2 inflammation when inhalers alone are not enough.",
    "hero_h1": "Appeal Your Dupixent Asthma Denial",
    "hero_subhead": "If you are still wheezing on high-dose inhalers, biologic therapy may be essential.",
    "intro": "Dupixent is often denied for asthma due to borderline lab criteria, questions about severity, or insurer preference for other biologics. A strong appeal shows that you meet guideline-based criteria and that your asthma remains unsafe without Dupixent.",
    "common_denial_reasons": [
      "Eosinophil count or FeNO not meeting strict thresholds",
      "Asthma not documented as severe or uncontrolled",
      "Insufficient documentation of high-dose inhaler and steroid use",
      "Plan prefers another biologic first"
    ],
    "how_we_help": "We help you and your clinician summarize ER visits, steroid bursts, spirometry, and biomarker data to show why Dupixent specifically is medically appropriate.",
    "cta": "Start your Dupixent asthma appeal.",
    "faq": [
      {
        "question": "What should my doctor highlight about my asthma?",
        "answer": "They should list exacerbations, hospitalizations, oral steroid courses, and how symptoms limit daily life. They should tie these to type 2 inflammation markers that support Dupixent use."
      },
      {
        "question": "Can I appeal if my eosinophil count is borderline?",
        "answer": "Yes. Your appeal can explain your clinical history, FeNO levels if available, and how your pattern fits guideline criteria even if a single lab value is borderline."
      },
      {
        "question": "What if my plan is removing Dupixent from formulary or switching to another biologic?",
        "answer": "If you're already stable on Dupixent and your insurer wants you to switch, you may have continuity of care rights. You can request a medical exception showing that switching biologics may destabilize your condition. See our continuity of care page for more information."
      }
    ],
    "evidence_snippets": [
      "Dupilumab reduces exacerbations and improves lung function in patients with moderate-to-severe asthma with type 2 inflammation.",
      "Biologic therapy can reduce dependence on systemic steroids, lowering the risk of steroid-related side effects.",
      "Guidelines endorse biologics like dupilumab for patients with uncontrolled asthma despite maximal inhaled therapy."
    ],
    "pubmed_search_terms": [
      "dupilumab severe asthma randomized trial",
      "type 2 inflammation asthma biologic dupilumab",
      "GINA guideline biologic therapy dupilumab"
    ],
    "assistance_programs": [
      {
        "name": "DUPIXENT MyWay Copay Card",
        "url": "https://www.dupixent.com/support-savings/copay-card",
        "description": "Pay as little as $0 per fill with commercial insurance. Max $13,000/year benefit."
      },
      {
        "name": "DUPIXENT MyWay Patient Support",
        "url": "https://www.dupixent.com/support-savings/dupixent-my-way",
        "description": "Benefits investigation, prior auth support, and patient assistance for uninsured or coverage gaps."
      }
    ]
  },
  "asthma-biologic-denial-omalizumab": {
    "slug": "asthma-biologic-denial-omalizumab",
    "title": "Appealing Xolair (Omalizumab) Asthma Denials",
    "default_procedure": "Xolair for Allergic Asthma",
    "default_condition": "Allergic Asthma",
    "tagline": "For allergic asthma, IgE-targeted therapy can be life-changing.",
    "hero_h1": "Appeal Your Xolair Asthma Denial",
    "hero_subhead": "If allergy-driven asthma is out of control, denying Xolair can be dangerous.",
    "intro": "Xolair is often denied for not hitting a narrow IgE range, weight band, or step-therapy path. Appeals that walk through your allergy history and exacerbations can reverse those decisions.",
    "common_denial_reasons": [
      "IgE level or weight not within policy table",
      "Insufficient documentation of perennial allergen sensitization",
      "Asthma not labeled as severe persistent",
      "Insurer prefers alternative therapies"
    ],
    "how_we_help": "We help you assemble allergy testing, exacerbation history, and inhaler use so your appeal clearly shows why Xolair is medically appropriate for your pattern of allergic asthma.",
    "cta": "Start your Xolair asthma appeal.",
    "faq": [
      {
        "question": "What allergy documentation should I include?",
        "answer": "Include skin or blood test results for perennial allergens (like dust mites or animal dander), plus notes connecting exposures to symptom flares."
      },
      {
        "question": "What if I’ve been on high-dose inhalers for years?",
        "answer": "Your appeal should make that clear, including any side effects or ongoing exacerbations despite treatment—this supports escalation to Xolair."
      }
    ],
    "evidence_snippets": [
      "Omalizumab reduces exacerbations and healthcare use in patients with moderate-to-severe allergic asthma.",
      "Targeting IgE can help patients whose asthma is driven by perennial allergen sensitization.",
      "Biologic therapy is recommended when standard inhaled regimens fail to provide adequate control."
    ],
    "pubmed_search_terms": [
      "omalizumab allergic asthma exacerbation reduction",
      "IgE targeted therapy severe persistent asthma",
      "omalizumab guideline severe allergic asthma"
    ],
    "assistance_programs": [
      {
        "name": "Xolair Co-pay Program",
        "url": "https://www.xolaircopay.com/",
        "description": "Pay as little as $0 per injection with commercial insurance. Up to $15,000/year for allergic asthma."
      },
      {
        "name": "Genentech Patient Foundation",
        "url": "https://www.genentech-access.com/patient/brands/xolair/how-we-help-you.html",
        "description": "Free medication for qualifying uninsured or underinsured patients meeting income requirements."
      }
    ]
  },
  "asthma-biologic-denial-mepolizumab": {
    "slug": "asthma-biologic-denial-mepolizumab",
    "title": "Appealing Nucala (Mepolizumab) Asthma Denials",
    "default_procedure": "Nucala for Eosinophilic Asthma",
    "default_condition": "Eosinophilic Asthma",
    "tagline": "Eosinophilic asthma is high risk—denials often ignore that.",
    "hero_h1": "Appeal Your Nucala Asthma Denial",
    "hero_subhead": "Eosinophilic asthma is high risk—denials often ignore that.",
    "intro": "Nucala is denied when eosinophil counts are questioned, documentation is incomplete, or insurers want a different biologic first. Appeals can show that your eosinophilic asthma remains uncontrolled and at high risk without Nucala.",
    "common_denial_reasons": [
      "Eosinophil counts not documented or not repeated",
      "Asthma not labeled as eosinophilic or severe",
      "Not enough steroid bursts or exacerbations documented",
      "Preference for an alternative eosinophil-targeting biologic"
    ],
    "how_we_help": "We help your clinician pull together lab trends, imaging, lung function, and exacerbation records to show why Nucala is medically necessary.",
    "cta": "Start your Nucala asthma appeal.",
    "faq": [
      {
        "question": "Do I need multiple eosinophil counts?",
        "answer": "Multiple measurements can help. Your appeal can include both historical and recent labs, especially if steroids temporarily lowered counts."
      },
      {
        "question": "How do I show that my asthma is eosinophilic?",
        "answer": "Your clinician can connect lab values, nasal or sinus disease, and response to steroids with the diagnosis of eosinophilic asthma."
      }
    ],
    "evidence_snippets": [
      "Mepolizumab reduces exacerbations and oral steroid use in patients with severe eosinophilic asthma.",
      "Eosinophilic inflammation is a key driver of exacerbations in a subset of asthma patients.",
      "Biologics targeting IL-5 or related pathways are standard options for severe eosinophilic asthma in guideline algorithms."
    ],
    "pubmed_search_terms": [
      "mepolizumab eosinophilic asthma randomized trial",
      "IL-5 inhibition severe eosinophilic asthma outcomes",
      "eosinophilic asthma biologic guideline mepolizumab"
    ],
    "assistance_programs": [
      {
        "name": "NUCALA Copay Program",
        "url": "https://www.nucala.com/nucala-copay-program/",
        "description": "Pay as little as $0 with commercial insurance. Up to $15,000/year benefit."
      },
      {
        "name": "GSK Patient Assistance Foundation",
        "url": "https://gskpaf.org/gsk/prescription-medicine-patient-assistance/nucala-uninsured/",
        "description": "Free medication for qualifying uninsured patients or those with Medicare."
      }
    ]
  },

  "eczema-biologic-denial-dupilumab": {
    "slug": "eczema-biologic-denial-dupilumab",
    "title": "Appealing Dupixent (Dupilumab) Eczema Denials",
    "default_procedure": "Dupixent for Atopic Dermatitis",
    "default_condition": "Atopic Dermatitis",
    "tagline": "Severe eczema is a systemic disease, not just a rash.",
    "hero_h1": "Appeal Your Dupixent Eczema Denial",
    "hero_subhead": "When skin is cracked, infected, and sleepless, denying Dupixent is not reasonable.",
    "intro": "Dupixent is often denied for atopic dermatitis because severity is under-documented, prior treatments are not listed, or plans prefer to avoid high-cost biologics. Appeals that clearly describe severity can change outcomes.",
    "common_denial_reasons": [
      "Disease not documented as moderate-to-severe",
      "Topical therapies or phototherapy not fully documented",
      "Age or dosing concerns for pediatric patients",
      "Plan questions long-term use"
    ],
    "how_we_help": "We help you document body areas involved, infections, sleep loss, and emotional distress to show Dupixent is medically necessary and guideline-consistent.",
    "cta": "Start your Dupixent eczema appeal.",
    "faq": [
      {
        "question": "How detailed should I be about my symptoms?",
        "answer": "Very detailed. Describe itch, pain, bleeding, infections, missed work or school, and how long flares last. Photos and dermatologist notes help."
      },
      {
        "question": "Can children be approved for Dupixent?",
        "answer": "Yes, many children meet indications. Your appeal should highlight pediatric dosing recommendations and the impact on growth, sleep, and development."
      },
      {
        "question": "What if my plan is removing Dupixent from formulary or switching me to another medication?",
        "answer": "If you're already stable on Dupixent and your insurer wants you to switch, you may have continuity of care rights. Switching biologics or systemic therapies in atopic dermatitis can destabilize skin control. See our continuity of care page for more information."
      }
    ],
    "evidence_snippets": [
      "Dupilumab significantly improves skin clearance and itch in moderate-to-severe atopic dermatitis.",
      "Effective treatment of atopic dermatitis improves sleep, work productivity, and mental health.",
      "Guidelines endorse systemic or biologic therapies when topical treatments are insufficient."
    ],
    "pubmed_search_terms": [
      "dupilumab moderate severe atopic dermatitis trial",
      "biologic therapy atopic dermatitis quality of life",
      "atopic dermatitis guideline systemic therapy dupilumab"
    ],
    "assistance_programs": [
      {
        "name": "DUPIXENT MyWay Copay Card",
        "url": "https://www.dupixent.com/support-savings/copay-card",
        "description": "Pay as little as $0 per fill with commercial insurance. Max $13,000/year benefit."
      },
      {
        "name": "DUPIXENT MyWay Patient Support",
        "url": "https://www.dupixent.com/support-savings/dupixent-my-way",
        "description": "Benefits investigation, prior auth support, and patient assistance for uninsured or coverage gaps."
      }
    ]
  },
  "eczema-biologic-denial-upadacitinib": {
    "slug": "eczema-biologic-denial-upadacitinib",
    "title": "Appealing Rinvoq (Upadacitinib) Eczema Denials",
    "default_procedure": "Rinvoq for Atopic Dermatitis",
    "default_condition": "Atopic Dermatitis",
    "tagline": "When topical and biologic options fail, targeted oral therapy may be necessary.",
    "hero_h1": "Appeal Your Rinvoq Eczema Denial",
    "hero_subhead": "Rinvoq is often reserved for the hardest cases—exactly where appeals matter most.",
    "intro": "Rinvoq is a JAK inhibitor used for moderate-to-severe atopic dermatitis when other options are inadequate. Insurers may deny it as too risky, experimental, or not medically necessary.",
    "common_denial_reasons": [
      "Not enough prior systemic or biologic therapy failures documented",
      "Concerns about JAK inhibitor safety profile without context",
      "Disease severity not clearly documented",
      "Age or comorbidity concerns not addressed"
    ],
    "how_we_help": "We help you and your dermatologist explain prior treatment failures, monitoring plans, and why Rinvoq’s benefits outweigh risks in your case.",
    "cta": "Start your Rinvoq eczema appeal.",
    "faq": [
      {
        "question": "How do we address safety concerns in the appeal?",
        "answer": "Your clinician can describe baseline labs, ongoing monitoring, and why benefits—such as preventing infections from open skin—are clinically important."
      },
      {
        "question": "What if I've already tried Dupixent or other biologics?",
        "answer": "List each prior systemic treatment, how long you used it, and why it was insufficient or intolerable. That strengthens the case for advancing to Rinvoq."
      }
    ],
    "evidence_snippets": [
      "Upadacitinib improves skin clearance and reduces itch in patients with refractory atopic dermatitis.",
      "For some patients, targeted oral therapies are needed after failure of biologic or conventional systemic treatments.",
      "Careful selection and monitoring can mitigate risks associated with JAK inhibitors."
    ],
    "pubmed_search_terms": [
      "upadacitinib atopic dermatitis randomized trial",
      "JAK inhibitor atopic dermatitis safety efficacy",
      "systemic therapy refractory atopic dermatitis upadacitinib"
    ],
    "assistance_programs": [
      {
        "name": "RINVOQ Complete Savings Card",
        "url": "https://www.rinvoq.com/resources/save-on-rinvoq-costs",
        "description": "Pay as little as $0/month with commercial insurance. Up to $14,000/year benefit."
      },
      {
        "name": "RINVOQ Complete Bridge Program",
        "url": "https://www.rinvoq.com/resources/rinvoq-complete",
        "description": "Free medication for up to 24 months while insurance coverage is delayed or denied."
      },
      {
        "name": "myAbbVie Assist",
        "url": "https://www.abbvie.com/patients/patient-assistance.html",
        "description": "Free medication for qualifying uninsured, underinsured, or unemployed patients."
      }
    ]
  },

  "migraine-med-denial-emgality": {
    "slug": "migraine-med-denial-emgality",
    "title": "Appealing Emgality (Galcanezumab) Denials",
    "default_procedure": "Emgality for Migraine Prevention",
    "default_condition": "Migraine",
    "tagline": "Chronic migraines are often under treated by insurance.",
    "hero_h1": "Appeal Your Emgality Denial",
    "hero_subhead": "If chronic migraine is disabling you, denying Emgality is not acceptable.",
    "intro": "Emgality is often denied until patients have failed a long list of older preventives. Appeals can show that you meet criteria and that Emgality is needed to reduce disability and emergency visits.",
    "common_denial_reasons": [
      "Not enough failed preventive medications documented",
      "Migraine frequency not clearly recorded",
      "Insurer prefers a different CGRP antibody",
      "Quantity limits or duration limits"
    ],
    "how_we_help": "We help you document headache days per month, disability, prior medication failures, and ER/urgent care visits to support Emgality coverage.",
    "cta": "Start your Emgality appeal.",
    "faq": [
      {
        "question": "How do I document my migraine burden?",
        "answer": "Use a headache diary or calendar showing number of migraine days, severity, and impact on work or school. Include any ER or urgent care visits."
      },
      {
        "question": "Can I appeal if I had side effects from older preventives?",
        "answer": "Yes. Note the side effects and how they limited use—this supports moving to a better-tolerated option like Emgality."
      }
    ],
    "evidence_snippets": [
      "Galcanezumab reduces monthly migraine days in patients with episodic and chronic migraine.",
      "CGRP monoclonal antibodies are specifically designed for migraine prevention and are often better tolerated than older preventives.",
      "Effective migraine prevention decreases disability and healthcare utilization."
    ],
    "pubmed_search_terms": [
      "galcanezumab Emgality chronic migraine randomized",
      "CGRP monoclonal antibody migraine prevention",
      "migraine disability reduction CGRP therapy"
    ],
    "assistance_programs": [
      {
        "name": "Emgality Savings Card",
        "url": "https://www.emgality.lilly.com/savings-support",
        "description": "Pay as little as $0/month for up to 12 months with commercial insurance. Max $4,900/year savings."
      },
      {
        "name": "Lilly Cares Foundation",
        "url": "https://www.lillycares.com/",
        "description": "Free medication for qualifying patients without commercial insurance and with low income, including some Medicare Part D patients."
      }
    ]
  },
  "migraine-med-denial-aimovig": {
    "slug": "migraine-med-denial-aimovig",
    "title": "Appealing Aimovig (Erenumab) Denials",
    "default_procedure": "Aimovig for Migraine Prevention",
    "default_condition": "Migraine",
    "tagline": "Step therapy shouldn't stop you from accessing the care you need.",
    "hero_h1": "Appeal Your Aimovig Denial",
    "hero_subhead": "Aimovig may be appropriate when multiple older preventives have failed.",
    "intro": "Aimovig is often denied due to strict step-therapy rules or incomplete documentation. A focused appeal can show that you meet standard criteria for CGRP therapy.",
    "common_denial_reasons": [
      "Fewer than required trialed preventive drugs documented",
      "Migraine days per month not clearly stated",
      "Insurer prefers a different CGRP agent",
      "Issues with prior authorization timing"
    ],
    "how_we_help": "We help you and your clinician summarize prior preventives, side effects, and migraine burden so Aimovig is seen as medically necessary.",
    "cta": "Start your Aimovig appeal.",
    "faq": [
      {
        "question": "Which prior medications should I mention?",
        "answer": "List beta-blockers, antiepileptics, antidepressants, or other preventives you’ve tried, including dose, duration, and why they failed or were stopped."
      },
      {
        "question": "Can I appeal if I previously used another CGRP drug?",
        "answer": "Yes. Explain response or side effects and why switching to Aimovig is appropriate now."
      }
    ],
    "evidence_snippets": [
      "Erenumab reduces monthly migraine days and improves quality of life in migraine patients.",
      "CGRP-targeted therapies provide a migraine-specific preventive option when older drugs fail.",
      "Long-term data suggest sustained benefit and tolerability for many patients."
    ],
    "pubmed_search_terms": [
      "erenumab Aimovig migraine randomized controlled",
      "CGRP receptor antagonist migraine prevention",
      "long term safety erenumab migraine"
    ],
    "assistance_programs": [
      {
        "name": "Aimovig Copay Card",
        "url": "https://www.aimovig.com/paying-for-aimovig",
        "description": "Pay as little as $5/month with commercial insurance. Up to $3,500 annual benefit."
      },
      {
        "name": "Aimovig Bridge Program",
        "url": "https://www.aimovigcopaycard.com/enroll",
        "description": "Free Aimovig for up to 12 doses while insurance coverage is pending."
      },
      {
        "name": "Amgen Safety Net Foundation",
        "url": "https://www.amgensafetynetfoundation.com/",
        "description": "Free medication for qualifying uninsured patients or those whose insurance excludes Aimovig."
      }
    ]
  },
  "migraine-med-denial-ajovy": {
    "slug": "migraine-med-denial-ajovy",
    "title": "Appealing Ajovy (Fremanezumab) Denials",
    "default_procedure": "Ajovy for Migraine Prevention",
    "default_condition": "Migraine",
    "tagline": "Monthly or quarterly dosing can simplify life with migraine.",
    "hero_h1": "Appeal Your Ajovy Denial",
    "hero_subhead": "Ajovy is one of several CGRP antibodies—appeals can justify why it’s the right one for you.",
    "intro": "Ajovy may be denied when insurers want you to try a different CGRP antibody or insist that older preventives are enough. Appeals should highlight your specific needs and prior experiences.",
    "common_denial_reasons": [
      "Failure to use insurer-preferred CGRP agent first",
      "Not meeting threshold for chronic or high-frequency migraine",
      "Incomplete documentation of prior preventive failures",
      "Questions about monthly vs. quarterly dosing"
    ],
    "how_we_help": "We help your clinician explain why Ajovy’s dosing schedule, response in your case, or side-effect profile makes it the most appropriate option.",
    "cta": "Start your Ajovy appeal.",
    "faq": [
      {
        "question": "Does it matter if my migraines are episodic or chronic?",
        "answer": "Yes. Your appeal should specify which pattern you have and reference data showing Ajovy’s benefit in that group."
      },
      {
        "question": "Can dosing schedule matter in an appeal?",
        "answer": "Absolutely. If quarterly dosing improves adherence or reduces burden, your clinician should spell that out."
      }
    ],
    "evidence_snippets": [
      "Fremanezumab reduces migraine frequency in both episodic and chronic migraine.",
      "Flexible monthly or quarterly dosing can support adherence and patient preference.",
      "CGRP monoclonal antibodies are recommended for patients with frequent migraines who fail standard preventives."
    ],
    "pubmed_search_terms": [
      "fremanezumab Ajovy episodic chronic migraine trial",
      "CGRP monoclonal antibody migraine quarterly dosing",
      "migraine guideline CGRP monoclonal antibody fremanezumab"
    ],
    "assistance_programs": [
      {
        "name": "Ajovy Savings Offer",
        "url": "https://www.ajovy.com/savings",
        "description": "Pay as little as $15 per prescription with commercial insurance. Annual limits apply."
      },
      {
        "name": "Teva Cares Foundation",
        "url": "https://www.tevacares.org/",
        "description": "Free medication for qualifying uninsured or underinsured patients meeting income criteria."
      }
    ]
  },
  "migraine-med-denial-nurtec": {
    "slug": "migraine-med-denial-nurtec",
    "title": "Appealing Nurtec ODT (Rimegepant) Denials",
    "default_procedure": "Nurtec ODT for Acute and Preventive Migraine Treatment",
    "default_condition": "Migraine",
    "tagline": "Medication for both stopping and helping prevent migraine attacks.",
    "hero_h1": "Appeal Your Nurtec Denial",
    "hero_subhead": "Nurtec is often denied on cost grounds or strict quantity limits.",
    "intro": "Nurtec ODT is a gepant used for acute migraine and, in some cases, prevention. Insurers often impose severe quantity limits or reject coverage entirely.",
    "common_denial_reasons": [
      "Quantity limits inconsistent with patient’s attack frequency",
      "Requirement to fail multiple triptans first",
      "Off-label use for prevention questioned",
      "Plan prefers a different gepant"
    ],
    "how_we_help": "We help you explain migraine frequency, failed triptans, and any contraindications that make Nurtec necessary for you.",
    "cta": "Start your Nurtec appeal.",
    "faq": [
      {
        "question": "How do I appeal quantity limits?",
        "answer": "Show your typical number of attacks per month and how strict limits lead to untreated attacks, ER visits, or missed work."
      },
      {
        "question": "What if I cannot take triptans?",
        "answer": "Have your clinician explain contraindications—such as heart disease or stroke risk—or intolerable side effects from triptans."
      }
    ],
    "evidence_snippets": [
      "Rimegepant provides relief for acute migraine and has evidence for preventive use with regular dosing.",
      "Gepants offer an option for patients who cannot use or do not respond to triptans.",
      "Adequate acute and preventive treatment reduces migraine-related disability."
    ],
    "pubmed_search_terms": [
      "rimegepant Nurtec acute migraine randomized",
      "rimegepant preventive migraine dosing trial",
      "gepant therapy migraine triptan contraindication"
    ],
    "assistance_programs": [
      {
        "name": "Nurtec ODT Copay Card",
        "url": "https://www.nurtec.com/savings",
        "description": "Pay as little as $0 for a 30-day supply with commercial insurance. Max $7,000/year benefit."
      },
      {
        "name": "Pfizer Patient Assistance Program",
        "url": "https://www.pfizerrxpathways.com/",
        "description": "Free medication for qualifying patients at or below 300% federal poverty level."
      }
    ]
  },
  "migraine-med-denial-ubrelvy": {
    "slug": "migraine-med-denial-ubrelvy",
    "title": "Appealing Ubrelvy (Ubrogepant) Denials",
    "default_procedure": "Ubrelvy for Acute Migraine Treatment",
    "default_condition": "Migraine",
    "tagline": "When triptans are not an option, gepants can be crucial.",
    "hero_h1": "Appeal Your Ubrelvy Denial",
    "hero_subhead": "Ubrelvy is often denied or heavily restricted, but appeals frequently succeed.",
    "intro": "Ubrelvy is a gepant used acutely to stop migraine attacks. Plans often restrict it to small quantities or deny it unless several triptans have failed.",
    "common_denial_reasons": [
      "Insufficient prior triptan trials",
      "Quantity limits too low for attack frequency",
      "Use in patients with perceived low migraine burden",
      "Preference for formulary alternatives"
    ],
    "how_we_help": "We help you document prior acute treatments, contraindications, and attack frequency to justify Ubrelvy at an appropriate quantity.",
    "cta": "Start your Ubrelvy appeal.",
    "faq": [
      {
        "question": "How many prior medications do I need to document?",
        "answer": "List all acute meds you’ve tried—over-the-counter and prescription—with responses and side effects. The more thorough, the better."
      },
      {
        "question": "Can I appeal even if I still have some triptan benefit?",
        "answer": "Yes. If triptans cause side effects, can’t be used often enough, or are unsafe given your risk factors, that still supports coverage for Ubrelvy."
      }
    ],
    "evidence_snippets": [
      "Ubrogepant is effective for acute treatment of migraine and is generally well tolerated.",
      "Gepants provide an option for patients with cardiovascular risk factors that limit triptan use.",
      "Timely acute treatment reduces the need for emergency care and shortens attack duration."
    ],
    "pubmed_search_terms": [
      "ubrogepant Ubrelvy acute migraine randomized",
      "gepant acute migraine cardiovascular risk",
      "ubrogepant efficacy safety migraine treatment"
    ],
    "assistance_programs": [
      {
        "name": "Ubrelvy Savings Card",
        "url": "https://www.ubrelvy.com/savings",
        "description": "Pay as little as $0/month with commercial insurance. Up to 13 fills per year."
      },
      {
        "name": "myAbbVie Assist",
        "url": "https://www.abbvie.com/patients/patient-assistance.html",
        "description": "Free medication for qualifying patients who have difficulty paying for their medicine."
      }
    ]
  },

  "insulin-pump-cgm-denial-dexcom": {
    "slug": "insulin-pump-cgm-denial-dexcom",
    "title": "Appealing Dexcom CGM Denials",
    "default_procedure": "Dexcom Continuous Glucose Monitor",
    "default_condition": "Diabetes",
    "tagline": "Real-time glucose data can prevent dangerous highs and lows.",
    "hero_h1": "Appeal Your Dexcom CGM Denial",
    "hero_subhead": "When finger sticks are not enough, Dexcom can be medically necessary.",
    "intro": "Dexcom CGMs are denied when plans claim that traditional glucose monitoring is sufficient, or that criteria like multiple daily injections are not clearly documented. Appeals can show how Dexcom improves safety and control.",
    "common_denial_reasons": [
      "Not enough documented hypoglycemia episodes",
      "Insufficient evidence of multiple daily insulin injections",
      "Use for type 2 diabetes questioned",
      "Preference for a different CGM"
    ],
    "how_we_help": "We help you compile logs of lows, highs, and variability, plus your insulin regimen, to demonstrate why Dexcom’s continuous data is necessary.",
    "cta": "Start your Dexcom appeal.",
    "faq": [
      {
        "question": "What data should I include?",
        "answer": "Include documented low readings, episodes where you needed help, night-time events, and any ER visits for hypo- or hyperglycemia."
      },
      {
        "question": "Can people with type 2 diabetes qualify?",
        "answer": "Yes, especially on intensive insulin regimens or with high hypoglycemia risk. Your appeal should highlight those factors."
      }
    ],
    "evidence_snippets": [
      "Continuous glucose monitoring reduces hypoglycemia and improves glycemic control compared with finger-stick monitoring alone.",
      "Real-time CGM data allow earlier intervention for rising or falling glucose levels.",
      "Improved glucose control reduces long-term complications and acute events."
    ],
    "pubmed_search_terms": [
      "Dexcom continuous glucose monitoring randomized trial",
      "real time CGM type 1 type 2 diabetes outcomes",
      "continuous glucose monitoring hypoglycemia risk reduction"
    ],
    "assistance_programs": [
      {
        "name": "Dexcom Patient Assistance Program",
        "url": "https://assistance.dexcom.com/",
        "description": "Discounts for qualifying patients, as low as $45 per 90-day supply for Type 1 diabetes patients meeting income criteria."
      },
      {
        "name": "Dexcom Pharmacy Savings Program",
        "url": "https://www.dexcom.com/en-us/savings-center",
        "description": "Save over 50% on standard monthly cash price at participating pharmacies."
      }
    ]
  },
  "insulin-pump-cgm-denial-freestyle-libre": {
    "slug": "insulin-pump-cgm-denial-freestyle-libre",
    "title": "Appealing FreeStyle Libre Denials",
    "default_procedure": "FreeStyle Libre Flash Glucose Monitoring",
    "default_condition": "Diabetes",
    "tagline": "Scanning a sensor is not a luxury—it's safer than guessing.",
    "hero_h1": "Appeal Your FreeStyle Libre Denial",
    "hero_subhead": "Libre gives continuous insight without constant finger sticks.",
    "intro": "FreeStyle Libre is often denied as unnecessary when finger-stick testing is available. Appeals can show how sensor data helps prevent severe highs and lows, especially for people on insulin.",
    "common_denial_reasons": [
      "Plan believes standard glucose testing is sufficient",
      "Not enough documented daily testing or insulin use",
      "Use in type 2 diabetes restricted",
      "Supplier or brand not preferred"
    ],
    "how_we_help": "We help you and your clinician show how Libre improves adherence, safety, and control compared with occasional finger-stick checks.",
    "cta": "Start your Libre appeal.",
    "faq": [
      {
        "question": "Should I include my current testing pattern?",
        "answer": "Yes. Show how often you realistically test now and why more frequent data from Libre would improve safety and control."
      },
      {
        "question": "What if I have trouble with finger sticks?",
        "answer": "Note pain, calluses, vision issues, or dexterity limits that make traditional testing difficult—these are strong arguments for Libre."
      }
    ],
    "evidence_snippets": [
      "Flash glucose monitoring improves time in range and reduces hypoglycemia in people with insulin-treated diabetes.",
      "Sensor-based monitoring can increase engagement and adherence to glucose monitoring.",
      "Better glucose data allow more precise insulin adjustments and lifestyle decisions."
    ],
    "pubmed_search_terms": [
      "FreeStyle Libre flash glucose monitoring trial",
      "flash glucose monitoring time in range hypoglycemia",
      "sensor based glucose monitoring insulin treated diabetes"
    ],
    "assistance_programs": [
      {
        "name": "MyFreeStyle Program",
        "url": "https://www.freestyle.abbott/us-en/myfreestyle-freestyle-libre-3.html",
        "description": "Eligible patients can receive one sensor at $0 copay. Free sensor offer for new users."
      },
      {
        "name": "FreeStyle Libre Copay Card",
        "url": "https://www.freestyle.abbott/us-en/support.html",
        "description": "Savings for commercially insured patients. Over 95% of commercial plans cover FreeStyle Libre."
      },
      {
        "name": "Abbott Patient Assistance Foundation",
        "url": "https://www.abbott.com/corpnewsroom/diabetes-care/at-a-crossroads-heres-how-to-get-help-for-diabetes.html",
        "description": "Free or reduced-cost sensors for patients meeting income and insurance criteria."
      }
    ]
  },
  "insulin-pump-denial-omnipod": {
    "slug": "insulin-pump-denial-omnipod",
    "title": "Appealing Omnipod Insulin Pump Denials",
    "default_procedure": "Omnipod Insulin Pump System",
    "default_condition": "Diabetes",
    "tagline": "Tubeless pump therapy can be the safest and most realistic option for some people.",
    "hero_h1": "Appeal Your Omnipod Pump Denial",
    "hero_subhead": "If multiple daily injections are not working, Omnipod may be medically necessary.",
    "intro": "Omnipod and other insulin pumps are denied when insurers believe injections are sufficient or another pump should be used. Appeals can show why a tubeless system is necessary for safety, adherence, or disability.",
    "common_denial_reasons": [
      "Not enough documented problems with multiple daily injections",
      "Not meeting criteria for insulin pump therapy",
      "Preference for a different pump brand",
      "Classified as convenience rather than medical necessity"
    ],
    "how_we_help": "We help you describe hypoglycemia risk, dawn phenomenon, injection site issues, and lifestyle factors that make Omnipod safer and more effective than injections.",
    "cta": "Start your Omnipod appeal.",
    "faq": [
      {
        "question": "Why does pump therapy count as medically necessary?",
        "answer": "Your clinician can explain how a pump allows finer dosing, better pattern management, and fewer highs/lows compared with injections."
      },
      {
        "question": "How do I justify Omnipod specifically?",
        "answer": "Mention factors like needle phobia, tubing entanglement risks, work or sports activities, or sensory issues that make tubeless therapy important."
      }
    ],
    "evidence_snippets": [
      "Insulin pump therapy can improve glycemic control and reduce hypoglycemia in selected patients.",
      "Tubeless pump systems may improve quality of life and adherence for some individuals.",
      "Pump therapy is particularly useful for patients requiring flexible basal rates and frequent dose adjustments."
    ],
    "pubmed_search_terms": [
      "insulin pump therapy glycemic control type 1",
      "tubeless insulin pump Omnipod quality of life",
      "insulin pump vs multiple daily injections outcomes"
    ],
    "assistance_programs": [
      {
        "name": "Omnipod Financial Assistance Program",
        "url": "https://www.omnipod.com/is-omnipod-right-for-me/coverage/financial-assistance",
        "description": "Copay card to reduce monthly out-of-pocket costs for commercially insured patients."
      },
      {
        "name": "Omnipod 5 Free Trial",
        "url": "https://www.omnipod.com/what-is-omnipod/omnipod-5",
        "description": "30-day free trial for new patients switching from injections or tubed pumps."
      }
    ]
  },
  "pep-denial-hiv-exposure": {
    "slug": "pep-denial-hiv-exposure",
    "title": "Appealing HIV PEP (Post-Exposure Prophylaxis) Denials",
    "default_procedure": "HIV Post-Exposure Prophylaxis (PEP)",
    "default_condition": "HIV Exposure",
    "tagline": "PEP is time-critical emergency prevention — coverage fights come second.",
    "hero_h1": "Appeal Your HIV PEP Denial",
    "hero_subhead": "If you might have been exposed to HIV, getting PEP fast is the emergency — we help you fight the bill after.",
    "intro": "PEP is a course of HIV medicines that should be started as soon as possible after a potential exposure. We encourage you to not wait for insurance and seek out treatment as soon as possible. This page focuses on what to do **after** you’ve gotten care and are facing a denial or a huge bill.",
    "common_denial_reasons": [
      "Insurer claims the exposure was not \"high risk\" enough for PEP",
      "Started PEP close to or slightly beyond a strict 72-hour cutoff",
      "Plan treating PEP as non-emergency pharmacy benefit only (no ER coverage)",
      "Lack of prior authorization even though treatment was urgent",
      "Denial of some components of the 3-drug regimen or follow-up labs"
    ],
    "how_we_help": "We help you explain the exposure, timing, and clinical recommendations in plain language, tie your situation to HIV prevention guidelines, and argue that PEP was urgent post-exposure care — not elective medication. We also help challenge denial of specific drugs or follow-up testing and fix common coding issues.",
    "cta": "Start your HIV PEP appeal.",
    "faq": [
      {
        "question": "What should I do *right now* if I think I’ve been exposed to HIV?",
        "answer": "We do not provide medical advice, but we strongly encourage you to consult a provider as soon as possible as PEP is most effective when started as soon as possible. We strongly encourage you not to wait for an insurance decision to seek care and look into community resources that can help in the meantime."
      },
      {
        "question": "Does it still make sense to appeal if I already finished PEP and only now got the denial?",
        "answer": "Yes. Many people only find out later that their PEP visit or medications weren’t fully covered. Your appeal can explain why PEP was clinically appropriate at the time, how quickly you presented, and what your provider recommended, and ask the plan to reconsider the charges."
      },
      {
        "question": "Can my insurer deny PEP because they think the risk was low?",
        "answer": "Your appeal can describe what actually happened (in terms you’re comfortable with) and reference clinical guidance that supports offering PEP for similar exposures. Plans shouldn’t substitute their own risk guesses for the judgment of clinicians using current guidelines."
      },
      {
        "question": "What if the problem is that different parts of the bill were denied?",
        "answer": "Sometimes the ER visit is covered but the pharmacy isn’t, or vice versa. Your appeal can argue that the visit, medication, and required labs were all part of one medically necessary PEP episode and should be considered together."
      },
      {
        "question": "Are there local resources that can help me besides my insurer?",
        "answer": "Yes. Many cities and states have HIV hotlines, AIDS service organizations, or health department programs that help people access PEP and navigate billing. You can search for \"HIV hotline\" plus your city or state, or call your local health department or an LGBTQ+ community health center to ask about PEP help and financial assistance."
      }
    ],
    "evidence_snippets": [
      "HIV PEP is most effective when started as soon as possible after a potential exposure and must generally be started within 72 hours; earlier is better.",
      "Standard PEP regimens are 3-drug antiretroviral combinations taken for 28 days with follow-up HIV testing.",
      "Clinical guidelines treat HIV exposure as a medical emergency and recommend initiating PEP immediately when indicated, with insurance coverage following standard emergency-care rules."
    ],
    "pubmed_search_terms": [
      "HIV post exposure prophylaxis timing 72 hours 28 days regimen",
      "nonoccupational HIV PEP guidelines United States",
      "emergency HIV exposure prophylaxis clinical outcomes"
    ],
    "assistance_programs": [
      {
        "name": "HIV.gov PEP Access and Assistance",
        "url": "https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/post-exposure-prophylaxis/accessing",
        "description": "Overview of how to access PEP quickly and manufacturer patient assistance programs that may provide PEP medications at low or no cost."
      },
      {
        "name": "Gilead Advancing Access",
        "url": "https://www.gileadadvancingaccess.com/",
        "description": "Patient assistance and co-pay support program for certain HIV medications commonly used in PEP regimens."
      },
      {
        "name": "State PrEP/PEP Assistance Programs (NASTAD directory)",
        "url": "https://nastad.org/prepcost-resources/state-prep-assistance-programs",
        "description": "State-level programs that may help with PEP and related lab costs for uninsured or under-insured people."
      }
    ]
  },

  "doxy-pep-denial": {
    "slug": "doxy-pep-denial",
    "title": "Appealing Doxy-PEP (Doxycycline Post-Exposure Prophylaxis) Denials",
    "default_procedure": "Doxycycline Post-Exposure Prophylaxis (Doxy-PEP) for STIs",
    "default_condition": "STI Prevention",
    "tagline": "Doxy-PEP is guideline-supported STI prevention for some patients — not experimental for everyone.",
    "hero_h1": "Appeal Your Doxy-PEP Denial",
    "hero_subhead": "For some MSM and trans women, taking doxycycline after sex is now part of standard STI prevention.",
    "intro": "Doxycycline post-exposure prophylaxis (doxy-PEP) is a newer STI prevention strategy where certain patients take doxycycline shortly after sex to reduce the risk of syphilis and chlamydia and, in some settings, gonorrhea. Current U.S. guidelines recommend doxy-PEP discussion and prescribing for specific groups, especially men who have sex with men and transgender women with a recent bacterial STI. Plans may deny coverage as \"experimental\" or \"not medically necessary\" even when you’re clearly in the guideline-supported group.",
    "common_denial_reasons": [
      "Classified as experimental or investigational despite guideline support for selected populations",
      "Plan says doxycycline is only covered for infections, not prevention",
      "Risk factors or recent STI history not clearly documented in the chart",
      "Confusion about dosing (e.g., 200 mg within 72 hours after sex) vs standard infection treatment"
    ],
    "how_we_help": "We help your clinician document your risk factors and recent STI history, show that you fall into a guideline-supported group for doxy-PEP, and explain that this is targeted, evidence-based prevention — not casual or indefinite antibiotic use.",
    "cta": "Start your doxy-PEP appeal.",
    "faq": [
      {
        "question": "Who do guidelines say doxy-PEP is appropriate for?",
        "answer": "Current U.S. guidance focuses on men who have sex with men and transgender women who have had a recent bacterial STI like syphilis, chlamydia, or gonorrhea, or who have ongoing high risk of exposure. Your appeal can show that your situation matches those criteria and that the decision was made with shared decision-making."
      },
      {
        "question": "How is doxy-PEP taken?",
        "answer": "Guidelines describe a single dose of doxycycline (often 200 mg) taken within a specified window after condomless sex. Your clinician’s note can clarify your dosing plan and emphasize that this is intermittent, post-exposure prevention — not daily long-term antibiotics."
      },
      {
        "question": "What if my plan is worried about antibiotic resistance or side effects?",
        "answer": "Your appeal can acknowledge these concerns and explain that your clinician is following guideline criteria, monitoring side effects, and periodically re-evaluating whether doxy-PEP is still appropriate, balancing individual and public health considerations."
      },
      {
        "question": "Should I also be getting regular STI screening while on doxy-PEP?",
        "answer": "Yes. Doxy-PEP is designed to complement, not replace, regular STI testing and other prevention strategies. Your appeal can mention that you’re in ongoing sexual health care, including routine screening and follow-up."
      }
    ],
    "evidence_snippets": [
      "Randomized trials have shown that doxy-PEP can substantially reduce syphilis and chlamydia infections and may reduce gonorrhea in some populations of men who have sex with men and transgender women.",
      "CDC clinical guidelines now recommend that clinicians discuss doxy-PEP with certain high-risk patients and consider prescribing it using shared decision-making.",
      "Guideline-based doxy-PEP uses targeted dosing after exposures, not continuous antibiotics, and includes regular STI screening and follow-up."
    ],
    "pubmed_search_terms": [
      "doxycycline postexposure prophylaxis bacterial sexually transmitted infection MSM transgender women",
      "CDC clinical guidelines doxy PEP 2024 syphilis chlamydia gonorrhea",
      "doxy PEP randomized trial STI prevention"
    ]
  },
  "flexitouch-plus-denial": {
    "slug": "flexitouch-plus-denial",
    "title": "Appealing Flexitouch Plus & Advanced Pneumatic Compression Device Denials",
    "default_procedure": "Flexitouch Plus or Similar Advanced Pneumatic Compression Device",
    "default_condition": "Lymphedema",
    "tagline": "For many people with lymphedema, advanced compression devices are medically necessary — not luxury massage gear.",
    "hero_h1": "Appeal Your Flexitouch Plus or Lymphedema Pump Denial",
    "hero_subhead": "When basic compression isn’t enough, advanced pneumatic compression can protect function, skin, and quality of life.",
    "intro": "Devices like Flexitouch Plus are advanced pneumatic compression systems used at home to treat lymphedema, including limb and head-and-neck lymphedema. Insurers often deny them by saying \"use standard compression only,\" demanding long conservative-therapy trials, or calling them experimental. In reality, many coverage policies do allow these devices when conservative measures haven’t worked and there is documented, persistent lymphedema.",
    "common_denial_reasons": [
      "\"Conservative therapy not exhausted\" (e.g., not enough weeks of bandaging, garments, elevation, exercise)",
      "No documentation of persistent swelling, skin changes, or functional limits",
      "Device labeled as experimental or not medically necessary",
      "Request for trunk/head-and-neck treatment when policy is written for limb-only devices",
      "Lack of clear physician plan of care or follow-up notes"
    ],
    "how_we_help": "We help you lay out your full lymphedema history: how long you’ve had swelling, infections, skin breakdown, or pain; what conservative measures you’ve actually tried and for how long; and how much function you’re losing. We also help your clinician reference coverage criteria and clinical studies showing that advanced pneumatic compression can reduce swelling and symptoms, especially when standard care hasn’t been enough.",
    "cta": "Start your Flexitouch Plus or lymphedema pump appeal.",
    "faq": [
      {
        "question": "What counts as \"conservative therapy\" for lymphedema devices?",
        "answer": "Most policies expect a documented period (often 4 weeks or more) of consistent use of compression garments or bandaging, exercise, and elevation, sometimes with complete decongestive therapy. Your appeal should list dates, therapies used, and why they were not enough by themselves."
      },
      {
        "question": "How do I show that I really need an advanced device instead of a basic pump or just garments?",
        "answer": "Your appeal can include limb or neck measurements over time, photos (if you’re comfortable), therapist notes, episodes of cellulitis, difficulty with daily activities, and any failure of simpler devices. If your lymphedema involves the trunk or head and neck, it’s especially important to show why a device designed for those areas is needed."
      },
      {
        "question": "Is Flexitouch Plus actually studied, or is it experimental?",
        "answer": "Clinical studies have evaluated advanced pneumatic compression devices, including Flexitouch systems, in people with limb and head-and-neck lymphedema. Trials have reported improvements in swelling, symptoms, and function compared with self-care alone in selected patients. Your appeal can cite that there is published evidence and that the device is FDA-cleared for lymphedema, even if your plan’s policy summary sounds cautious."
      },
      {
        "question": "What documentation should my doctor or therapist provide?",
        "answer": "Helpful items include a formal lymphedema diagnosis, stage, limb/trunk/neck measurements, photos, a signed plan of care, notes from at least one recent in-person visit, and documentation of conservative measures already tried. If you’ve had hospitalizations or recurrent infections related to lymphedema, include those too."
      }
    ],
    "evidence_snippets": [
      "Coverage policies for home pneumatic compression devices often require a documented trial of conservative therapy and persistent lymphedema before covering advanced devices.",
      "Prospective and randomized studies of advanced pneumatic compression devices, including Flexitouch systems, have reported reductions in limb or head-and-neck swelling, symptom burden, and sometimes healthcare utilization.",
      "Advanced pneumatic compression devices are FDA-cleared for lymphedema treatment and are typically considered when standard garments and basic pumps are insufficient."
    ],
    "pubmed_search_terms": [
      "advanced pneumatic compression device lymphedema Flexitouch randomized trial",
      "home pneumatic compression lymphedema coverage criteria conservative therapy",
      "head and neck lymphedema Flexitouch Plus clinical outcomes"
    ]
  },
  "continuity-of-care-formulary-change": {
    "slug": "continuity-of-care-formulary-change",
    "title": "Appealing Formulary Changes Using Continuity of Care",
    "default_procedure": "Medication Continuity of Care Exception",
    "tagline": "When your medication worked and the plan changes, you have rights.",
    "hero_h1": "Appeal Your Formulary Change Denial",
    "hero_subhead": "If your medication is removed from formulary or moved to a higher tier, you can request an exception to continue your treatment.",
    "intro": "Insurance plans frequently change their formularies (drug lists), sometimes removing medications that patients are already taking or moving them to higher cost-sharing tiers. Federal regulations and many state laws protect patients by requiring insurers to grant continuity of care exceptions when a formulary change would disrupt ongoing treatment. This page helps you understand your rights and appeal for continued coverage.",
    "common_denial_reasons": [
      "Drug removed from formulary — preferred alternative available",
      "Drug moved to non-preferred or specialty tier with higher cost-sharing",
      "Step therapy required before covering your current medication",
      "Insurer claims equivalent medication is available",
      "Mid-year formulary change with insufficient notice",
      "Prior authorization now required for previously covered drug"
    ],
    "how_we_help": "We help you document how long you've been taking the medication, your treatment history and response, why switching would be medically harmful, and cite the federal and state laws that protect you from disruptive formulary changes. We also help you request a medical exception based on continuity of care.",
    "cta": "Start your formulary change appeal.",
    "faq": [
      {
        "question": "What federal protections exist for formulary changes?",
        "answer": "Often insurers must provide a reasonable transition policy when they remove a drug from formulary. You have the right to request a medically necessary exception, and many state laws add additional protections against non-medical switching."
      },
      {
        "question": "Can my insurer force me to switch medications mid-year?",
        "answer": "Many states have 'non-medical switching' or 'continuity of care' laws that prevent insurers from forcing stable patients to switch medications mid-plan-year. Even without state law, federal regulations require a reasonable transition process. Your appeal can argue that switching now would disrupt your care."
      },
      {
        "question": "What should I include in my appeal?",
        "answer": "Document how long you've been on the medication, how well it's working, any previous failed treatments, and why switching would be harmful. A letter from your doctor explaining medical necessity is essential. Include specific details about your condition stability and any risks of changing medications."
      },
      {
        "question": "What if my insurer says a generic or alternative is available?",
        "answer": "Your appeal can explain why the alternative is not appropriate for you — for example, if you've tried it before and it didn't work, if you have allergies or intolerances, or if the medications are not truly therapeutically equivalent for your condition."
      },
      {
        "question": "How long can I get a continuity of care exception?",
        "answer": "Transition supplies are often limited (e.g., 30-90 days), but you can request a longer exception for the remainder of the plan year. Some states require coverage for the full plan year once granted. Check your state's laws and plan documents."
      }
    ],
    "evidence_snippets": [
      "Often health plans must have a transition policy when drugs are removed from formulary, and patients have the right to request a medically necessary exception.",
      "Many states have enacted non-medical switching laws that protect patients from being forced to change medications that are working well, especially for conditions like cancer, HIV, epilepsy, and mental health.",
      "Clinical research shows that medication switching can lead to adverse outcomes, treatment failures, and increased healthcare costs — supporting the medical necessity of continuity of care."
    ],
    "pubmed_search_terms": [
      "medication switching adverse outcomes treatment stability",
      "formulary exclusion patient impact continuity care",
      "non-medical switching legislation insurance coverage"
    ]
  },
  "humira-formulary-removal": {
    "slug": "humira-formulary-removal",
    "title": "Appealing Humira (Adalimumab) Formulary Removal",
    "default_procedure": "Humira (Adalimumab) Continuity of Care",
    "tagline": "Stable on Humira? You have the right to request continued coverage.",
    "hero_h1": "Fight Your Humira Formulary Removal",
    "hero_subhead": "Some major PBMs removed Humira, but you can appeal for continuity of care.",
    "intro": "CVS Caremark, Express Scripts, and other major pharmacy benefit managers have removed Humira from many formularies in favor of biosimilars. If you've been stable on Humira and your insurer wants you to switch, you have rights under federal continuity of care regulations and potentially state non-medical switching laws.",
    "common_denial_reasons": [
      "Humira removed from formulary — biosimilar required",
      "Plan requires switch to preferred biosimilar (Hyrimoz, Hadlima, etc.)",
      "Humira no longer covered at current tier",
      "Prior authorization required for continued Humira use",
      "Non-formulary exception denied"
    ],
    "how_we_help": "We help you document your treatment history with Humira, explain why biosimilar switching may be harmful in your case, and cite federal and state laws that protect stable patients from forced medication changes.",
    "cta": "Start your Humira continuity of care appeal.",
    "faq": [
      {
        "question": "Why are insurers removing Humira from formularies?",
        "answer": "Multiple adalimumab biosimilars have entered the market since 2023, and PBMs have negotiated deals to prefer certain biosimilars. CVS Caremark, Express Scripts, and OptumRx all excluded Humira from many formularies for 2025 in favor of lower-cost biosimilar options."
      },
      {
        "question": "Are biosimilars truly the same as Humira?",
        "answer": "Biosimilars are highly similar but not identical to the reference product. While FDA-approved biosimilars are considered safe and effective, some patients experience different responses when switching. Your appeal can document any concerns about switching."
      },
      {
        "question": "What if I've tried a biosimilar and it didn't work?",
        "answer": "Document your experience with the biosimilar — side effects, efficacy issues, or other problems. This strengthens your case for continued Humira coverage as medically necessary."
      },
      {
        "question": "Can I get Humira covered even if it's not on formulary?",
        "answer": "Yes. Depending on your plan and it's regulator you can request a non-formulary exception based on medical necessity. Your doctor should provide a letter explaining why Humira specifically is needed for your care."
      }
    ],
    "evidence_snippets": [
      "many health plans must provide a transition process when drugs are removed from formulary, and patients can request exceptions based on medical necessity.",
      "The FDA requires that biosimilars demonstrate no clinically meaningful differences from the reference product, but individual patient responses may vary.",
      "Studies on biosimilar switching show mixed results, and some patients may experience changes in efficacy or tolerability when switching from a reference biologic."
    ],
    "pubmed_search_terms": [
      "adalimumab biosimilar switching efficacy safety",
      "non-medical switching biologic therapy outcomes",
      "humira biosimilar interchangeability patient outcomes"
    ],
    "assistance_programs": [
      {
        "name": "HUMIRA Complete Savings Card",
        "url": "https://www.humira.com/humira-complete/cost-and-copay",
        "description": "Pay as little as $5 per month with commercial insurance. Not valid with government insurance."
      },
      {
        "name": "myAbbVie Assist",
        "url": "https://www.abbvie.com/patients/patient-assistance.html",
        "description": "Patient assistance for uninsured or underinsured patients who qualify based on income."
      }
    ]
  },
  "stelara-formulary-removal": {
    "slug": "stelara-formulary-removal",
    "title": "Appealing Stelara (Ustekinumab) Formulary Removal",
    "default_procedure": "Stelara (Ustekinumab) Continuity of Care",
    "tagline": "Stable on Stelara? Fight for continued coverage as biosimilars enter the market.",
    "hero_h1": "Fight Your Stelara Formulary Removal",
    "hero_subhead": "Some major PBMs are removing Stelara in 2025-2026, but you can appeal for continuity of care.",
    "intro": "Health Alliance, Navitus, UnitedHealthcare, and other plans are removing Stelara from formularies in 2025-2026 as multiple ustekinumab biosimilars enter the market. If you've been stable on Stelara and your insurer wants you to switch to a biosimilar, you have rights under federal continuity of care regulations.",
    "common_denial_reasons": [
      "Stelara removed from formulary — biosimilar required",
      "Plan requires switch to Steqeyma, Yesintek, or other biosimilar",
      "Stelara no longer covered at current tier",
      "Prior authorization now required for Stelara",
      "Non-formulary exception denied"
    ],
    "how_we_help": "We help you document your treatment history with Stelara, explain why biosimilar switching may be harmful in your case, and cite federal and state laws that protect stable patients from forced medication changes.",
    "cta": "Start your Stelara continuity of care appeal.",
    "faq": [
      {
        "question": "Why are insurers removing Stelara from formularies?",
        "answer": "Multiple ustekinumab biosimilars entered the market in 2024-2025, and PBMs are negotiating deals to prefer lower-cost biosimilar options. By early 2026, most major PBMs will have removed Stelara from national formularies."
      },
      {
        "question": "When is Stelara being removed from my plan?",
        "answer": "Timelines vary: Health Alliance removed Stelara April 2025, Navitus/OptumRx in July 2025, UnitedHealthcare in September 2025, and Blue KC/Express Scripts in January 2026. Check with your specific plan for details."
      },
      {
        "question": "What biosimilars are being preferred instead?",
        "answer": "Common preferred biosimilars include Steqeyma, Yesintek, and private-label versions from Lumicera (OptumRx) and Quallent (Express Scripts). Plans may differ in which specific biosimilar they prefer."
      },
      {
        "question": "Can I get Stelara covered even after it's removed from formulary?",
        "answer": "Yes. You can request a non-formulary exception. However, some plans may require you to pay the difference in cost between Stelara and the preferred biosimilar."
      }
    ],
    "evidence_snippets": [
      "Ustekinumab (Stelara) has demonstrated long-term efficacy and safety in psoriasis, psoriatic arthritis, and inflammatory bowel disease.",
      "Non-medical switching of stable patients from biologic originators to biosimilars may carry risks of altered efficacy or immunogenicity."
    ],
    "pubmed_search_terms": [
      "ustekinumab biosimilar switching efficacy safety",
      "non-medical switching biologic therapy inflammatory bowel disease",
      "stelara biosimilar interchangeability patient outcomes"
    ],
    "assistance_programs": [
      {
        "name": "Janssen CarePath Savings Program",
        "url": "https://www.jnjwithme.com/patient/stelara/cost-support/",
        "description": "Eligible patients with commercial insurance may pay as little as $5 per dose. Not for government insurance."
      },
      {
        "name": "Johnson & Johnson Patient Assistance Foundation",
        "url": "https://www.jnjpaf.org/",
        "description": "Patient assistance for uninsured or underinsured patients who meet income requirements."
      }
    ]
  },
  "entyvio-formulary-removal": {
    "slug": "entyvio-formulary-removal",
    "title": "Appealing Entyvio (Vedolizumab) Formulary Removal",
    "default_procedure": "Entyvio (Vedolizumab) Continuity of Care",
    "default_condition": "Inflammatory Bowel Disease",
    "tagline": "Stable on Entyvio for IBD? Fight for continued coverage.",
    "hero_h1": "Fight Your Entyvio Formulary Removal",
    "hero_subhead": "Express Scripts is excluding Entyvio IV in 2026 — but you can appeal especially for continuity of care.",
    "intro": "Express Scripts is excluding Entyvio IV from the National Preferred Formulary effective 2026. If you have Crohn's disease or ulcerative colitis and are stable on Entyvio, you may have rights under continuity of care regulations.",
    "common_denial_reasons": [
      "Entyvio IV excluded from formulary effective July 2026",
      "Plan requires switch to alternative biologic",
      "Prior authorization now required",
      "Non-formulary exception denied"
    ],
    "how_we_help": "We help you document your IBD treatment history with Entyvio, explain why switching biologics may trigger disease flares, and cite federal and state laws that protect stable patients from forced medication changes.",
    "cta": "Start your Entyvio continuity of care appeal.",
    "faq": [
      {
        "question": "Why is this particularly concerning for IBD patients?",
        "answer": "Switching biologics in IBD can trigger disease flares, and patients may develop antibodies that make returning to their original medication difficult. Your appeal should emphasize the risks of switching when stable."
      },
      {
        "question": "What alternatives might my plan prefer?",
        "answer": "Plans may push for other biologics or JAK inhibitors. Your appeal can explain why Entyvio's gut-selective mechanism is specifically appropriate for your case, especially if you've tried other medications."
      },
      {
        "question": "Can I get Entyvio covered even after exclusion?",
        "answer": "Yes. You can request a non-formulary exception based on medical necessity. Your gastroenterologist should provide a letter explaining why Entyvio specifically is needed."
      }
    ],
    "evidence_snippets": [
      "Vedolizumab (Entyvio) has a gut-selective mechanism of action, which may offer advantages for patients who have failed or are intolerant to systemic immunosuppressants.",
      "Switching biologics in IBD carries risk of disease flare, loss of response, and development of anti-drug antibodies.",
    ],
    "pubmed_search_terms": [
      "vedolizumab inflammatory bowel disease switching biologics outcomes",
      "IBD biologic switching disease flare anti-drug antibodies",
      "vedolizumab gut selective mechanism ulcerative colitis Crohn"
    ],
    "assistance_programs": [
      {
        "name": "EntyvioConnect",
        "url": "https://www.entyvio.com/copay-support",
        "description": "Eligible patients with commercial insurance may pay as little as $5 per infusion. Not for government insurance."
      },
      {
        "name": "Takeda Patient Assistance Program",
        "url": "https://www.takeda.com/en-us/what-we-do/patient-services/",
        "description": "Patient assistance for uninsured or underinsured patients who qualify."
      }
    ]
  },
  "skyrizi-formulary-removal": {
    "slug": "skyrizi-formulary-removal",
    "title": "Appealing Skyrizi (Risankizumab) Formulary Removal",
    "default_procedure": "Skyrizi (Risankizumab) Continuity of Care",
    "default_condition": "Psoriasis",
    "tagline": "Stable on Skyrizi for psoriasis or IBD? Fight for continued coverage.",
    "hero_h1": "Fight Your Skyrizi Formulary Removal",
    "hero_subhead": "Some plans are excluding Skyrizi in 2026 — but you can appeal for continuity of care.",
    "intro": "Some PBMs are excluding Skyrizi from formularies in 2026. If you have psoriasis, psoriatic arthritis, or Crohn's disease and are stable on Skyrizi, you have rights under federal continuity of care regulations.",
    "common_denial_reasons": [
      "Skyrizi excluded from formulary",
      "Plan requires switch to alternative biologic (Cosentyx, biosimilar, etc.)",
      "Step therapy required before Skyrizi",
      "Prior authorization now required",
      "Non-formulary exception denied"
    ],
    "how_we_help": "We help you document your treatment history with Skyrizi, explain why switching biologics may trigger disease flares, and cite federal and state laws that protect stable patients from forced medication changes.",
    "cta": "Start your Skyrizi continuity of care appeal.",
    "faq": [
      {
        "question": "Can I get Skyrizi covered even after exclusion?",
        "answer": "Yes. You can request a non-formulary exception based on medical necessity. Your dermatologist or rheumatologist should provide a letter explaining why Skyrizi is specifically needed."
      }
    ],
    "evidence_snippets": [
      "Risankizumab (Skyrizi) selectively targets IL-23, showing high rates of skin clearance in plaque psoriasis and efficacy in psoriatic arthritis and Crohn's disease.",
      "Switching biologics in psoriasis and psoriatic arthritis can result in disease flare and incomplete response to subsequent agents."
    ],
    "pubmed_search_terms": [
      "risankizumab plaque psoriasis IL-23 clinical trial",
      "biologic switching psoriasis loss of response",
      "risankizumab psoriatic arthritis Crohn disease efficacy"
    ],
    "assistance_programs": [
      {
        "name": "Skyrizi Complete Savings Card",
        "url": "https://www.skyrizi.com/skyrizi-complete/save-on-skyrizi-costs",
        "description": "Eligible patients with commercial insurance may pay as little as $5 per dose. Not for government insurance."
      },
      {
        "name": "myAbbVie Assist",
        "url": "https://www.abbvie.com/patients/patient-assistance.html",
        "description": "Patient assistance for uninsured or underinsured patients who qualify based on income."
      }
    ]
  },
  "tremfya-formulary-removal": {
    "slug": "tremfya-formulary-removal",
    "title": "Appealing Tremfya (Guselkumab) Formulary Removal",
    "default_procedure": "Tremfya (Guselkumab) Continuity of Care",
    "default_condition": "Psoriasis",
    "tagline": "Stable on Tremfya for psoriasis? Fight for continued coverage.",
    "hero_h1": "Fight Your Tremfya Formulary Removal",
    "hero_subhead": "Express Scripts is excluding Tremfya in 2026 — but you can appeal for continuity of care.",
    "intro": "Express Scripts is excluding Tremfya from the National Preferred Formulary in 2026. If you have psoriasis or psoriatic arthritis and are stable on Tremfya, you have rights under federal continuity of care regulations.",
    "common_denial_reasons": [
      "Tremfya excluded from formulary",
      "Plan requires switch to alternative biologic",
      "Step therapy required before Tremfya",
      "Prior authorization now required",
      "Non-formulary exception denied"
    ],
    "how_we_help": "We help you document your treatment history with Tremfya, explain why switching biologics may trigger disease flares, and cite federal and state laws that protect stable patients from forced medication changes.",
    "cta": "Start your Tremfya continuity of care appeal.",
    "faq": [
    ],
    "evidence_snippets": [
      "Guselkumab (Tremfya) selectively targets IL-23, showing high rates of skin clearance in plaque psoriasis and efficacy in psoriatic arthritis.",
      "Switching biologics in psoriasis can result in disease flare and may not achieve the same level of clearance as the original medication.",
    ],
    "pubmed_search_terms": [
      "guselkumab plaque psoriasis IL-23 clinical trial",
      "biologic switching psoriasis loss of response outcomes",
      "guselkumab psoriatic arthritis efficacy safety"
    ],
    "assistance_programs": [
      {
        "name": "Janssen CarePath Savings Program",
        "url": "https://www.janssencarepath.com/tremfya",
        "description": "Eligible patients with commercial insurance may pay as little as $5 per dose. Not for government insurance."
      },
      {
        "name": "Johnson & Johnson Patient Assistance Foundation",
        "url": "https://www.jnjpaf.org/",
        "description": "Patient assistance for uninsured or underinsured patients who meet income requirements."
      }
    ]
  },
  "skilled-nursing-denial": {
    "slug": "skilled-nursing-denial",
    "title": "Appealing Skilled Nursing Facility Denials",
    "default_procedure": "Skilled Nursing Facility (SNF) Care",
    "tagline": "UHC Medicare Advantage SNF denials increased 9x from 2019 to 2022: fight back.",
    "hero_h1": "Appeal Your Skilled Nursing Facility Denial",
    "hero_subhead": "Post-hospital care is essential for recovery. Don't be discharged too early.",
    "intro": "Skilled nursing facility denials have exploded, especially in Medicare Advantage plans. Between 2019 and 2022, SNF denials increased 9-fold, often driven by AI algorithms rather than clinical judgment. The good news: over 80% of appealed SNF denials are overturned, but fewer than 1% of patients appeal. You have rights — use them.",
    "common_denial_reasons": [
      "Patient no longer meets skilled care criteria",
      "Custodial care only — not skilled nursing",
      "Discharge to home is appropriate",
      "Maximum benefit reached",
      "Prior authorization expired"
    ],
    "how_we_help": "We help you document why skilled nursing care remains medically necessary, including specific skilled services needed (wound care, IV medications, PT/OT, complex medication management) and risks of premature discharge.",
    "cta": "Start your SNF appeal before you're discharged.",
    "faq": [
      {
        "question": "Can I stay in the SNF while I appeal?",
          "answer": "Often, under Medicare, you can request a 'fast appeal' and remain in the facility while your case is reviewed. Ask for a written denial notice and file immediately."
      },
      {
        "question": "What if the insurer says I can continue care at home?",
        "answer": "Your appeal should document why home care isn't safe or feasible: caregiver limitations, home environment issues, or medical complexity requiring 24/7 skilled oversight."
      }
    ],
    "evidence_snippets": [
      "Premature discharge from skilled nursing facilities is associated with higher hospital readmission rates.",
      "Medicare guidelines require coverage when skilled nursing or rehabilitation services are needed on a daily basis.",
      "Continued SNF care is medically necessary when the patient requires skilled services that cannot safely be provided in a less intensive setting.",
      "Refusal of Recovery: How Medicare Advantage Insurers Have Denied Patients Access to Post-Acute Care"
    ],
    "pubmed_search_terms": [
      "skilled nursing facility discharge outcomes readmission",
      "Medicare SNF coverage criteria medical necessity",
      "post-acute care denial Medicare Advantage"
    ],
    "alternatives": [
      "Home health care with visiting nurses may be an option if you have adequate support at home.",
      "Some long-term acute care hospitals (LTACHs) provide a higher level of care if SNF isn't sufficient.",
      "Ask about swing bed programs at community hospitals which combine acute and SNF-level care."
    ]
  },
  "home-health-denial": {
    "slug": "home-health-denial",
    "title": "Appealing Home Health Care Denials",
    "default_procedure": "Home Health Care / Home Nursing Services",
    "tagline": "Medicare's 'homebound' requirement trips up many patients — learn how to appeal.",
    "hero_h1": "Appeal Your Home Health Care Denial",
    "hero_subhead": "You shouldn't have to choose between leaving home and losing coverage.",
    "intro": "Home health care denials often hinge on the 'homebound' requirement and whether you need 'skilled' nursing care. Medicare Advantage plans are increasingly using narrow interpretations to deny home health services, even when your doctor has ordered them. Understanding what qualifies as homebound and skilled care is key to winning your appeal.",
    "common_denial_reasons": [
      "Patient not homebound",
      "Skilled care not required",
      "Services are maintenance only",
      "Caregiver can provide this care",
      "Frequency of visits not justified"
    ],
    "how_we_help": "We help you document your homebound status (leaving home requires considerable effort, assistance, or poses medical risk) and why skilled nursing or therapy services are medically necessary.",
    "cta": "Start your home health appeal.",
    "faq": [
    ],
    "evidence_snippets": [
      "Home health services reduce hospital readmissions and improve outcomes for patients recovering from illness, injury, or surgery.",
      "The homebound requirement is met when leaving home requires considerable effort or assistance, not complete inability to leave.",
      "Skilled nursing services are medically necessary when the complexity of the patient's condition requires professional assessment and intervention."
    ],
    "pubmed_search_terms": [
      "home health care outcomes hospital readmission prevention",
      "Medicare home health homebound criteria definition",
      "skilled nursing home health medical necessity"
    ],
    "alternatives": [
      "Adult day programs may provide supervision and therapy while preserving home health eligibility.",
      "Telehealth visits may supplement in-person home health for some services.",
      "Community-based waiver programs may provide additional home care services in some states."
    ]
  },
  "joint-replacement-denial": {
    "slug": "joint-replacement-denial",
    "title": "Appealing Knee and Hip Replacement Denials",
    "default_procedure": "Total Knee or Hip Replacement",
    "tagline": "Joint replacement is one of the most successful surgeries — insurers shouldn't block it.",
    "hero_h1": "Appeal Your Joint Replacement Denial",
    "hero_subhead": "When conservative treatment fails, surgery is the answer.",
    "intro": "Knee and hip replacements are among the most successful surgeries performed, with high satisfaction rates and dramatic quality-of-life improvements. Yet insurers frequently deny them, claiming you haven't tried enough conservative treatments or the surgery isn't 'medically necessary.' If you're living with severe joint pain that limits your daily activities, you deserve surgery.",
    "common_denial_reasons": [
      "Insufficient conservative treatment trial",
      "BMI too high for surgery",
      "Not medically necessary",
      "Imaging doesn't show severe enough damage",
      "Must try injections or physical therapy first"
    ],
    "how_we_help": "We help you document your pain level, functional limitations, failed conservative treatments (PT, injections, medications), and imaging results that support surgical intervention.",
    "cta": "Start your joint replacement appeal.",
    "faq": [
      {
        "question": "How much conservative treatment is 'enough'?",
        "answer": "Most guidelines suggest 3-6 months of conservative treatment including PT, anti-inflammatory medications, and possibly injections. Your appeal should list everything you've tried, how long you tried it, and why it didn't work."
      },
      {
        "question": "What if my BMI is above their cutoff?",
        "answer": "BMI cutoffs vary and are controversial. Your appeal can cite studies showing successful outcomes at higher BMIs, your surgeon's assessment of surgical risk, and why delaying surgery may worsen outcomes."
      },
      {
        "question": "Do I need X-rays showing 'bone-on-bone'?",
        "answer": "Not necessarily. Imaging is one factor, but clinical symptoms matter too. Your appeal should describe your pain, functional limitations, and your surgeon's assessment, not just imaging findings."
      }
    ],
    "evidence_snippets": [
      "Total joint replacement is a cost-effective intervention that significantly improves quality of life and functional status.",
      "Delaying medically necessary joint replacement can lead to muscle atrophy, deconditioning, and poorer surgical outcomes.",
      "Patient-reported pain and functional limitation are important indicators for joint replacement, independent of radiographic severity."
    ],
    "pubmed_search_terms": [
      "total knee replacement outcomes quality of life",
      "joint replacement surgical criteria medical necessity",
      "delay hip replacement outcomes deconditioning"
    ],
    "alternatives": [
      "Partial knee replacement may be an option for some patients with localized arthritis.",
      "Joint preservation procedures like osteotomy may delay the need for replacement in younger patients.",
      "Ask about outpatient joint replacement programs which may have different coverage criteria."
    ]
  },
  "out-of-network-emergency-denial": {
    "slug": "out-of-network-emergency-denial",
    "title": "Appealing Out-of-Network Emergency Room Denials",
    "default_procedure": "Emergency Room Services",
    "tagline": "Federal law protects you from surprise ER bills — insurers must comply.",
    "hero_h1": "Appeal Your Out-of-Network ER Denial",
    "hero_subhead": "The No Surprises Act protects you. Make your insurer follow the law.",
    "intro": "Since 2022, the No Surprises Act helps protect patients from surprise bills when they receive emergency care at out-of-network facilities. Yet insurers continue to improperly deny or underpay these claims. You normally cannot be balance-billed more than your in-network cost-sharing, and your insurer must pay the emergency facility appropriately. If your claim was denied or you received a surprise bill, you have strong appeal rights.",
    "common_denial_reasons": [
      "Out-of-network provider",
      "Emergency not verified",
      "Post-stabilization care not covered",
      "Claim filed incorrectly",
      "Balance billing by provider"
    ],
    "how_we_help": "We help you document the emergency nature of your visit, cite the No Surprises Act protections, and explain why your insurer must cover the claim at in-network cost-sharing levels.",
    "cta": "Start your emergency care appeal.",
    "faq": [
      {
        "question": "What is the No Surprises Act?",
        "answer": "Federal law since January 2022 that protects patients from surprise bills when receiving emergency care, even at out-of-network facilities. Your insurer must cover the claim and you only owe in-network cost-sharing."
      },
      {
        "question": "Can I be balance-billed for emergency care?",
          "answer": "Normally no. Under the No Surprises Act, out-of-network emergency providers cannot balance bill you for more than your in-network deductible and coinsurance. Report violations to your state insurance department. Unfortunately there are exceptions (including ground ambulances)."
      },
      {
        "question": "What about care after I was stabilized?",
        "answer": "Some post-stabilization care at out-of-network facilities can be protected until you can safely be transferred. Your appeal should document that you were not stable enough to transfer."
      }
    ],
    "evidence_snippets": [
      "The No Surprises Act requires insurers to cover emergency services at out-of-network facilities without requiring prior authorization.",
      "Patients cannot be charged more than in-network cost-sharing for emergency services regardless of network status.",
      "Emergency medical conditions are defined as those requiring immediate medical attention to prevent serious health consequences."
    ],
    "pubmed_search_terms": [
      "surprise medical billing emergency department policy",
      "out of network emergency care patient protections",
      "No Surprises Act emergency services implementation"
    ],
    "alternatives": [
      "File a complaint with your state insurance department if you receive a surprise balance bill.",
      "Request the Independent Dispute Resolution process if your insurer and provider can't agree on payment.",
      "Contact the CMS No Surprises Help Desk at 1-800-985-3059 for assistance."
    ]
  }
}
